INTERIM REPORT ON OPERATIONS OF THE DIASORIN GROUP AT SEPTEMBER 30, 2015
Third quarter 2015

DiaSorin S.p.A.
Via Crescentino (no building No.) - 13040 Saluggia (VC)
Tax I.D. and Vercelli Company Register n.13144290155

CONTENTS

Board of Directors, Board of Statutory Auditors and Independent Auditors

Board of Directors (elected on April 22, 2013)

Chairman	Gustavo Denegri
Deputy Chairman	Michele Denegri
Chief Executive Officer	Carlo Rosa (1)
Directors	Antonio Boniolo Chen Menachem Even Enrico Mario Amo Giuseppe Alessandria (2) (3) Franco Moscetti (2) Maria Paola Landini (2) Roberta Somati (2) Eva Desana Stefano Altara (4) Ezio Garibaldi

Board of Statutory Auditors

Chairman	Roberto Bracchetti
Statutory Auditors	Andrea Caretti Ottavia Alfano
Alternates	Bruno Marchina Maria Carla Bottini

Independent Auditors Deloitte & Touche S.p.A.

COMMITTEES

Control and Risks Committee	Franco Moscetti (Chairman) Enrico Mario Amo Roberta Somati
Compensation Committee	Giuseppe Alessandria (Chairman) Roberta Somati Michele Denegri
Nominating Committee	Franco Moscetti (Chairman) Giuseppe Alessandria Michele Denegri
Related-party Committee	Franco Moscetti (Coordinator) Giuseppe Alessandria Roberta Somati

(1) General Manager
(2) Independent Director
(3) Lead Independent Director
(4) Director Stefano Altara was appointed by the Shareholders' Meeting on April 23, 2014.

The Group

DiaSorin is an Italian multinational Group and a global leader in the market for in vitro diagnostics. DiaSorin is listed on the MTA (automated stock market) in the FTSE Italia Mid Cap Index, organized and managed by Borsa Italiana S.p.A.

For over 40 years the Group has been developing, producing and commercializing **diagnostic tests** for a wide range of clinical areas.

DiaSorin tests are designed for hospital and private testing laboratories in the market of **immunodiagnostics** and **molecular diagnostics.**

Immunodiagnostics

In this segment, DiaSorin develops, produces and markets **immunoreagent kits** based on 3 different detection techniques.

Chemiluminescence / CLIA	Colorimetry / ELISA	Radioimmunometry / RIA
DEVELOPMENT: early 1990s	**DEVELOPMENT**: 1980s	**DEVELOPMENT**: 1960s
SIGNAL: generated by markers marked with chemiluminescent molecules.	**SIGNAL**: generated by colorimetric markers.	**SIGNAL**: generated by radioactive markers.
TECHNOLOGY: ▪ It can be adapted to products and instruments with features offering a **high level of usage flexibility** in terms of menus and the performance speed of the test. ▪ It is used to develop products in proprietary formats in the area of **closed systems** (cartridges capable of working only on the system developed by the particular company).	**TECHNOLOGY**: ▪ It can perform diagnostic tests with the use of minimally sophisticated instrumentation; ▪ It can automate some of the manual operations performed by laboratory staff.	**TECHNOLOGY**: ▪ It is employed for some products capable of providing results that cannot be delivered by other technologies; ▪ It is used for tests that have to be carried out manually by experienced technicians.
PROCESSING TIMES: 30-45 minutes	**PROCESSING TIMES**: 3-4 hours	**PROCESSING TIMES**: >4 hours

DiaSorin supplies its customers with instruments that make it possible to carry out the diagnostic investigation automatically through the use of reagents.

CLIA **ELISA**

DiaSorin produces **reagents** that are biological components whose purpose is detecting the presence of specific elements (virus, hormones, etc.) in patient's blood sample.

These reagents are **high-tech diagnostic products** with a **high level of specificity** that can detect the presence, **also in small quantity**, of the element to be searched in the patient's sample.

Through its constant commitment aimed at enriching its offering, DiaSorin exceeded the target of **114 immunodiagnostic products** available on CLIA technology, out of which **31 specialty tests**, dedicated to the most clinical areas tested in laboratory.

This result enabled DiaSorin to become the Company with the **broadest test menu on CLIA technology worldwide**, confirming its vocation as the **Diagnostics Specialist**.

MOLECULAR DIAGNOSTICS

DiaSorin considers molecular diagnostics a strategic technological project for its own business and invests in Research and Development in this area to develop high-reliable and excellent products. In this segment DiaSorin provides end laboratory with an automated solution to implement the **three phases** required to deliver the final diagnostic result.



DiaSorin supplies its customers with instruments for nucleic acid extraction from different biological samples (LIAISON IXT and BULLET Pro) and to diagnose and monitor Onco-Haematology parameters and several infectious diseases (LIAISON IAM) through the use of its reagents.

EXTRACTION

Bullet Pro®

AMPLIFICATION AND DIAGNOSTIC PROCESS

CLINICAL AREAS

DiaSorin has always provided hospitals and laboratories with **state-of-the art diagnostic systems and solutions**.

Its competitive strength relies not only on its efficient and high technological products and services but also on **an increasingly wide and diversified range of products** covering all the main areas for the benefit of the health and prevention of an increasingly number of patients.

The company works in the following clinical areas:

	Infectious Diseases	Infectious diseases represent one of the major causes of death in the world. The growth of infectious diseases incidence has led to a continuous need for novel diagnostic tests to detect the presence of new infectious agents and improve the performance of those already launched onto the market. The growing number of diagnostic tests performed every day in a routine lab required the development of tests that are easy to perform and quick in providing results for faster diagnosis and therapy. Since 1970, DiaSorin has started to develop a product portfolio in the infectious disease clinical area and since 2001 the Company has launched a wide range of new CLIA products**,** featuring unique tests for the diagnosis of infectious diseases on LIAISON analysers.
	Bone and Mineral Metabolism	The diseases connected to bone and calcium metabolism continue to increase all over the world; DiaSorin offers a comprehensive range of immunoassays for their treatment. Among the several diagnostic parameters, DiaSorin is today recognized as a global leader in the Vitamin D test that today is considered the gold standard within the Scientific Community and thanks to which the Group has set the standard since 1985. DiaSorin's Bone & Mineral Metabolism products are unrivalled for quality, reliability and fast results. Clinicians can rely on accurate results to diagnose and monitor bone disorders. Furthermore, in 2014 DiaSorin has launched the first fully automated 1,25 Vitamin D test on CLIA technology.
	Endocrinology	The disorders of the endocrine system are connected to a complex group of glands *(thyroid, parathyroid, pancreas, ovaries, testes, adrenal, pituitary and hypothalamus)* producing hormones that control activities of our body. Diseases and disorders of the endocrine system can be grouped into several different areas: ▪ diabetes ▪ thyroid function ▪ fertility ▪ growth ▪ adrenal function ▪ gastroenterology. Since 1968 DiaSorin began to develop a portfolio of products to be used in the endocrinology field. Most of them are now available on CLIA technology.

	Hypertension	According to WHO and to the American Heart Association, Hypertension is one of the major risk factors for cardiovascular diseases. Today 1 billion people worldwide have high blood pressure and this number is expected to increase to 1.56 billion people by the year 2025, equal to 25% of the adult population. Hypertension is prevalent in developing as well as in developed countries. DiaSorin offers a unique fully automated panel for the diagnosis of a form of hypertension (Primary Aldosteronism), through two key tests (Aldosterone and Renin) on CLIA technology.
	Oncology	Every year about 10 million people are diagnosed with cancer resulting in over 6 million deaths. Cancer is considered the second most common cause of death in industrialized countries. Tumour markers are biological substances produced by the tumour cells, generally found in very low concentrations in normal individuals. Tumour cells can be measured in blood and other body fluids. DiaSorin offers important products to be used in diagnostic monitoring of these markers for screening, diagnosis and monitoring the disease's progression.
	Gastrointestinal Infections	Gastrointestinal infections affect mainly newborns/children, or elderly populations and immunocompromised patients and can be potentially serious. Diagnosis of gastrointestinal infections is largely performed through laboratory tests used for culture or antigen detection from stool specimens. Today DiaSorin offers the most complete and fully automated menu for the diagnosis of the most recurrent infections *(Clostridium Difficile Toxins A & B, Clostridium Difficile GDH, Helicobacter Pylori, EHEC E. Coli, Adenovirus and Rotavirus).* Lastly, DiaSorin has recently launched the first completely automated test for *Calprotectin* inflammatory levels.
	Autoimmunity	Autoimmune diseases are one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age. Researchers have identified 80-100 different autoimmune diseases and suspect at least 40 additional diseases of having an autoimmune basis. These diseases can be chronic and life-threatening as a hyperactive immune system attacks normal tissues as if they were foreign organisms. DiaSorin, through its experience and commitment to research, is a leading company in this growing market, with a complete line of immunodiagnostic specialty tests *(rheumatology, gastroenterology, diagnosis of thrombosis and vasculitis).*
	Cardiac and brain damages	Acute myocardial infarction and resulting complications are among the primary causes of mortality in the western world. Modern *biochemical markers* play a consolidated role in the diagnosis and even in the risk stratification of patients suffering from ischemic myocardial disease. During the last decade the analysis of *Neurobiochemical markers for brain damage* has attracted increasing attention in a variety of Central Nervous System disorders. These markers are expected to be useful tools for diagnosis, monitoring or prognosis of brain damaged patients. DiaSorin outstrips its competitors in both clinical areas, thanks to a full range of products available on CLIA technology.

A GLOBAL PRESENCE

The Group headed by DiaSorin S.p.A. is comprised of **23 companies** and **4 branches** on **5 continents.**

The Group's manufacturing organization consists of several facilities located in Europe, USA and Africa.



Head office location	**Companies**
Saluggia Italy	Group's Parent Company
Stillwater USA	DiaSorin Inc.
Dietzenbach Germany	DiaSorin Deutschland GmbH
Dublin Ireland	DiaSorin Ireland Ltd
Dartford UK	DiaSorin S.p.A-UK Branch
Kyalami South Africa	DiaSorin South Africa (Pty) Ltd

In Europe, United States, Mexico, Brazil, China, Australia and Israel, the DiaSorin Group sells its products mainly through its commercial subsidiaries that are part of the DiaSorin Group.

In countries where the Group does not have a direct presence, it operates through an international network of more than 80 independent distributors.

STRUCTURE OF THE DIASORIN GROUP AT SEPTEMBER 30, 2015



CONSOLIDATED FINANCIAL HIGHLIGHTS

Income statement *(in thousands of euros)*	**3rd quarter 2015**	**3rd quarter 2014**	**01.01 - 09.30 2015**	**01.01 - 09.30 2014**
Net revenues	123,232	109,025	368,376	325,796
Gross profit	85,031	72,424	251,365	218,335
EBITDA (1)	45,026	40,018	136,424	118,095
Operating result (EBIT)	36,615	32,150	111,692	95,538
Net profit for the period	23,230	21,311	72,051	61,284

Statement of financial position *(in thousands of euros)*	**09/30/2015**	**12/31/2014**
Capital invested in non-current assets	212,671	214,741
Net invested capital	320,314	317,231
Net financial position	231,868	166,342
Shareholders’ equity	552,182	483,573

Statement of cash flows *(in thousands of euros)*	**3rd quarter 2015**	**3rd quarter 2014**	**01.01 - 09.30 2015**	**01.01 - 09.30 2014**
Net cash flow for the period *	34,883	35,283	31,654	18,890
Free cash flow (2)	35,454	32,058	74,768	71,158
Capital expenditures	5,871	7,132	22,751	22,273
Number of employees			1,654	1,615

Unaudited data

* Including investments amounting to 30 million euros in bank term deposit opened in the first nine months of 2015.

(1) Looking at the data on the Table, the Board of Directors defines EBITDA as the “operating result (EBIT)” before amortization of intangibles and depreciation of property, plant and equipment.

(2) Free cash flow is the cash flow from operating activities, counting utilizations for capital expenditures but before interest payments and acquisitions of companies and business operations.

INTERIM REPORT ON OPERATIONS

Foreword

This interim report on operations at September 30, 2015 (hereinafter referred to as the "Quarterly Report") was prepared in accordance with international accounting principles (International Accounting Standards - IAS and International Financial Reporting Standards - IFRS) and the corresponding interpretations (Standing Interpretations Committee - SIC and International Financial Reporting Interpretations Committee - IFRIC) published by the International Accounting Standards Boards (IASB). More specifically, it is being presented in condensed form, in accordance with the international accounting principle that governs interim financial reporting (IAS 34), as adopted by the European Union, and complies with the requirements of Article 154-ter, Sections 2 and 3, of Legislative Decree No. 58 of February 24, 1998.

The accounting principles applied to prepare this consolidated quarterly report are consistent with those used for the annual consolidated financial statements at December 31, 2014, except as otherwise stated in the Notes to the Interim Consolidated Financial Statements – paragraph New accounting principles.

Key events in the third quarter of 2015

In July, DiaSorin announced the company signed a distribution partnership agreement with Beckman Coulter Diagnostics, a global leader in clinical diagnostics, for the commercialization in China of DiaSorin Hepatitis B, C and HIV tests on DiaSorin LIAISON XL LAS connected to Beckman Coulter's leading automation solutions, the Power Express and Power Processor automated sample processing systems.
Through this agreement DiaSorin will pursue its strategy to target large-size hospitals in China (ca. 8,000 CLASS IIA and III hospitals), where there is a growing need to provide fully automated solutions able to run both clinical chemistry and immunoassays on the same platform.

In September, DiaSorin launched 2 new molecular diagnostic tests, Iam PML-RARA Detection bcr1,3 and Iam PML-RARA Discrimination bcr2, available on the market outside the U.S. When used together, the new tests allow reliable, complete and extremely fast detection (15 minutes versus the 4 hours normally required to carry out the test) of the PML-RARA translocation, which is the genetic cause of "Fulminant Leukemia", technically called Acute Promyelocytic Leukemia, which is considered the most aggressive type of blood cancer that, if not identified in time, is fatal.

The foreign exchange market

In the first nine months of 2015, the average exchange rate of the euro lost value against almost all currencies used by the Group compared with the same period in 2014. Particularly, the euro lost value against the U.S. dollar (ca. -18 percentage points), the Chinese yuan (-17 percentage points), the South African Rand (around -6 percentage points) and the Australian dollar (-1 percentage point). In this context worth mentioning is the Brazilian real that depreciated by 14 percentage points against the euro.

In the third quarter of 2015, the average exchange rate of the euro versus the U.S. dollar was down 16 percentage points. The euro depreciated also against the Chinese yuan (-14 percentage points) while it appreciated vis-à-vis the Brazilian real (over +30 percentage points), the Australian dollar (+7 percentage points) and the South African rand (over +1 percentage point).

The exchange rate of the euro at September 30, 2015 depreciated by around 8 percentage points versus the U.S. dollar decreasing from 1.2141 recorded at the end of 2014 to 1.1203 at September 30, 2015.

The exchange rates impacted significantly on the Group's operating performance of the period.

The table below provides a comparison of the average and end-of-period exchange rates for the periods under comparison concerning the main currencies used by the Group (Source: Banca d'Italia).

Currency	Average exchange rates				Exchange rates at		
	01.01 - 09.30 2015	01.01 - 09.30 2014	3rd quarter 2015	3rd quarter 2014	09/30/2015	09/30/2014	12/31/2014
U.S. dollar	1.1144	1.3549	1.1117	1.3256	1.1203	1.2583	1.2141
Brazilian real	3.5257	3.1028	3.9340	3.0137	4.4808	3.0821	3.2207
British pound	0.7271	0.8118	0.7173	0.7938	0.7385	0.7773	0.7789
Swedish kronor	9.3709	9.0405	9.4293	9.2052	9.4083	9.1465	9.3930
Swiss franc	1.0621	1.2180	1.0723	1.2115	1.0915	1.2063	1.2024
Czech koruna	27.3547	27.5043	27.0755	27.6189	27.1870	27.5000	27.7350
Canadian dollar	1.4038	1.4819	1.4540	1.4422	1.5034	1.4058	1.4063
Mexican peso	17.3653	17.7720	18.2680	17.3879	18.9768	16.9977	17.8679
Israeli shekel	4.3344	4.7322	4.2793	4.6593	4.4001	4.6474	4.7200
Chinese yuan	6.9641	8.3544	7.0083	8.1734	7.1206	7.7262	7.5358
Australian dollar	1.4631	1.4760	1.5331	1.4326	1.5939	1.4442	1.4829
South African rand	13.7010	14.5356	14.4516	14.2700	15.4984	14.2606	14.0353
Norwegian krone	8.8174	8.2761	9.1378	8.2754	9.5245	8.1190	9.0420
Polish zloty	4.1571	4.1752	4.1877	4.1747	4.2448	4.1776	4.2732

REVIEW OF THE GROUP'S OPERATING PERFORMANCE AND FINANCIAL POSITION

OPERATING PERFORMANCE IN THE THIRD QUARTER OF 2015

In the third quarter of 2015, the DiaSorin Group's **revenues totalled 123,232 thousand euros** (109,025 thousand euros in the third quarter of 2014), up 13% or 14,207 thousand euros compared with the same period of 2014 (about +7% at constant exchange rates). The difference between the two growth rates is due to the appreciation of the US dollar and the Chinese yuan which partly offset the depreciation of the Brazilian real and Australian dollar.

Again in the third quarter of 2015 CLIA sales reported un upward trend, net of Vitamin D, with an increase of 27.3% (+22.5% at constant exchange rates) driven also by the good performance of novel 1,25 Vitamin D test, Infectious Diseases and Prenatal Screening. Noteworthy is the constant growth of Stool Tests that have been recently launched on the market.

In line with the previous quarter and forecasts, Vitamin D sales recorded a 14.2% increase (+2.5% at constant exchange rates), also due to the new agreement underwritten with Quest in the United States.

The abovementioned results contrasted with the physiological decline of the contribution provided by RIA and ELISA technologies, which are more dated and work on open systems.

The **gross profit** totalled **85,031 thousand euros**, up 17.4% compared with 72,424 thousand euros in the third quarter of 2014. The ratio of gross profit to revenues was equal to 69% (66.4% in 2014). The increase was mainly due to the different product mix of sales recorded in the quarters under comparison, in addition to the the different geographic mix (and its currency effect).

In the third quarter of 2015, **EBITDA** amounted to **45,026 thousand euros**, up 12.5% or 5,008 thousand euros compared with 40,018 thousand euros in the third quarter of 2014. EBITDA incidence to revenues was equal to 36.5%, in line with 2014. The rise compared to last year is attributed to a growth in gross profit, a lower incidence of operating costs while it is negatively impacted by translation adjustments on commercial items. When excluding the impact of the exchange rates from the quarters under comparison, EBITDA was up 9.3% and equal to about 37.5 percentage points of revenues.

EBIT amounted to **36,615 thousand euros,** up 13.9% compared with 32,150 thousand euros in the third quarter of 2014, equal to 29.7% of revenues and substantially in line with the third quarter of 2014.

In the third quarter of 2015**, net financial expenses** totalled **1,283 thousand euros**, compared with net financial income of 81 thousand euros in the third quarter of 2014, mainly as a result of the exchange rate fluctuations.

In the third quarter of 2015**, income taxes** totalled **12,102 thousand euros** (10,920 thousand euros in 2014), with a slightly higher tax rate equal to 34.3%, compared with a 33.9% tax rate in 2014, as a result of the computation of the Group's taxable profit across the different geographical areas in the periods under comparison.

The **net profit** amounted to **23,230 thousand euros,** up 9% or 1,919 thousand euros compared with the third quarter 2014. The net profit was equal to 18.9% of revenues in the third quarter of 2015 (19.5% of revenues in the third quarter of 2014).

CONSOLIDATED INCOME STATEMENT

(in thousands of euros)	**3rd quarter 2015**	**as a% of revenues**	**3rd quarter 2014**	**as a% of revenues**
Sales and service revenues	123,232	100.0%	109,025	100.0%
Cost of sales	(38,201)	31.0%	(36,601)	33.6%
Gross profit	**85,031**	**69.0%**	**72,424**	**66.4%**
Sales and marketing expenses	(23,496)	19.1%	(21,592)	19.8%
Research and development costs	(6,254)	5.1%	(6,177)	5.7%
General and administrative expenses	(13,728)	11.1%	(12,377)	11.4%
Total operating expenses	**(43,478)**	**35.3%**	**(40,146)**	**36.8%**
Other operating income (expense)	(4,938)	4.0%	(128)	0.1%
EBIT	**36,615**	**29.7%**	**32,150**	**29.5%**
Net financial income (expense)	(1,283)	1.0%	81	0.1%
Profit before taxes	**35,332**	**28.7%**	**32,231**	**29.6%**
Income taxes	(12,102)	9.8%	(10,920)	10.0%
Net profit	**23,230**	**18.9%**	**21,311**	**19.5%**
EBITDA (1)	**45,026**	**36.5%**	**40,018**	**36.7%**

Unaudited data.

(1) The Company defines EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

Net Revenues

In the third quarter of 2015, revenues totalled **123,232 thousand euros** (109,025 thousand euros in the third quarter of 2014). A breakdown of revenues by geographic region of destination is as follows:

Breakdown of revenues by geographic region

(in thousands of euros)	**3rd quarter 2015**	**3rd quarter 2014**	**% Change at current exchange rates**	**% Change at constant exchange rates**
Europa and Africa	55,720	51,795	7.6%	6.5%
North America	33,295	26,736	24.5%	4.8%
Asia Pacific	24,420	19,358	26.1%	15.7%
Central and South America	9,797	11,136	-12.0%	-0.6%
Total	**123,232**	**109,025**	**13.0%**	**7.0%**





Europe and Africa

Europe and Africa sales region generated sales equal to 55,720 thousand euros, up 7.6 percentage points (+6.5% at constant exchange rates) compared with 51,795 thousand euros in the third quarter of 2014. In detail:

i) decrease of 2% in sales generated in Italy (+ 0.5% in the local market)* following the delayed start of some important orders and the downward trend in RIA and ELISA sales which partly offset the good performance of Vitamin D;

ii) growth of 10.5% in the German subsidiary's sales (-1.3% in the local market)*, mainly driven by the strong performance of 1,25 Vitamin D, together with Vitamin D and Stool testing panel;

iii) stable sales in France (-7.5% in the local market)* due to increased CLIA sales offsetting the negative effect deriving from the decline in Vitamin D sales (reduction in reimbursement following the healthcare reform occurred in 2014);

* EDMA latest data available

iv) growth in all the countries of the area where the Group has a direct presence. Stable trend in markets served through distributors’ network (equal to +0.3%), despite socio-political tension in Russia.

North America

In the third quarter of 2015, the North America sales region reported revenues of 33,295 thousand euros, up 24.5% (+4.8% at constant exchange rates) compared with 26,736 thousand euros in the third quarter of 2014. This change is the net result of the following factors:

i) constant growth in sales of CLIA products in U.S., net of Vitamin D, with a gain of 39.4 percentage points, also due to the agreement signed with LabCorp concerning mainly Infectious Diseases and Prenatal Screening tests as well as increased sales in 1,25 Vitamin D;

ii) better performance of Vitamin D sales (+6.1%) that were positively impacted by the new agreement signed with Quest laboratories. This agreement has more than offset the reduced revenues in Vitamin D resulting from the price pressure.

Asia Pacific

In the third quarter of 2015, revenues of the Asia Pacific sales region amounted to 24,420 thousand euros, up 26.1% at current exchange rates (+15.7% at constant exchange rates) compared with 19,358 thousand euros in the third quarter of 2014. Specifically:

i) growth of 43.2 percentage points in local currency recorded in the Chinese market, resulting from the success of LIAISON XL automated platform and CLIA products. This upward trend more than offset the natural sales contraction of ELISA products;

ii) sales growth in local currency (+1.5%in local currency) carried out in the Australian market, positively impacted by higher sales of CLIA reagents, net of Vitamin D (+29.4%) that has more than offset the decline in Vitamin D sales volume deriving from the reduction in reimbursement following the healthcare reform. Noteworthy is the growth of 1,25 Vitamin D and Infectious Diseases panel.

iii) increase in revenues generated through distributors in markets where the Group does not have a direct presence (+1.3% at current exchange rates).

Central and South America

In the third quarter of 2015, the Latin American sales region recorded revenues of 9,797 thousand euros, down 12 percentage points (-0.6% at constant exchange rates) compared with 11,136 thousand euros in the same period of 2014. This is the net result of:

i) lower sales in the Brazilian market (-6.5% in local currency). This trend is partly due to the overall economic crisis affecting the country ad partly to disruptions of some important local distributors;

ii) growth in the Mexican subsidiary's sales (+7.6% in local currency). Against the previous quarter trend higher instruments sales have been recorded in connection with the start of an important tender;

iii) sales increased by 9.8% in the area served through distributors, as a result of the upward trend of all CLIA panels.

Breakdown of revenues by technology

% of revenues contributed	**3rd quarter 2015**	**3rd quarter 2014**
CLIA Tests	76.7%	70.7%
ELISA Tests	11.1%	14.7%
INSTRUMENT SALES and OTHER REVENUES	10.4%	11.7%
RIA Tests	1.0%	2.3%
MOLECULAR DIAGNOSTICS	0.8%	0.6%
Total	**100.0%**	**100.0%**





The following provides the main elements of revenues by technology:

i) growth of 27.3% (22.5% at constant exchange rates) in sales generated from CLIA products, net of Vitamin D;

ii) upward trend in Vitamin D sales amounting to +14.2% (+2.5% at constant exchange rates), resulting from the agreement signed with Quest in the U.S.

iii) increase in the installed base: 88 new instruments have been placed in the period, for a total of 6,232 installed units.

Lastly, the data in the table reflect the steady physiological decline of the contribution provided by the RIA and ELISA technologies, both functioning on open systems.

Operating performance

In the third quarter of 2015, the gross profit totalled 85,031 thousand euros, up 17.4 percentage points compared with the same period in 2014, mainly as a result of higher sales and a different geographic and product mix of the quarters under comparison, as already mentioned.

Operating expenses amounted to 43,478 thousand euros, with an increase of 3.332 thousand euros compared with the third quarter of 2014 (+8.3%). The ratio of operating expenses to total revenues decreased to 35.3% from 36.8% in 2014. The foreign exchange market negatively impacted this item for about 1.6 million euros: net of this effect the increase would be equal to about 4 percentage points. A detailed breakdown of operating expenses is provided below.

In the third quarter of 2015, sales and marketing expenses totalled 23,496 thousand euros, up by 1,904 thousand euros or 8.8% compared with 2014 (21,592 thousand euros). In addition to the costs incurred to support the sale force, this item includes costs to support the launch of new products and expenses related to the technical support for instruments at customers' facilities. The increase in operating expenses is attributable to higher business volumes, together with the exchange rate effect. The ratio of sales and marketing expenses to revenues decreased from 19.8% to 19.1%.

Research and development costs amounted to 6,254 thousand euros, up 1.2% compared with the third quarter of 2014 (6,177 thousand euros) and refer mainly to activities concerning the development of new products. The ratio of research and development costs to revenues amounted to 5.1 percentage points (5.7% in 2014).

General and administrative expenses amounted to 13,728 thousand euros, up 10.9% compared with the third quarter of 2014 (12,377 thousand euros in 2014). Their ratio to total revenues equal to 11.1 percentage points (11.4% in 2014). The increase is the net result of the abovementioned negative translation effect and partly of higher labour costs, including costs incurred for the 2014 stock option plan (313 thousand euros in the third quarter of 2015, compared with 192 thousand euros in the third quarter of 2014).

Other operating expenses equal to 4,938 thousand euros (128 thousand euros in the third quarter of 2014) include 1,244 thousand euros in additions to the allowances for doubtful accounts (91 thousand euros in 2014). This item includes also 538 thousand euros in tax expenses (473 thousand euros in 2014) and a negative translation adjustment of 3,065 thousand euros on commercial items (a positive translation adjustment of 451 thousand euros in 2014) arising from the depreciation of the Brazilian real.

In the third quarter of 2015, EBITDA amounted to 45,026 thousand euros (40,018 thousand euros in 2014) up by 5,008 thousand euros or 12.5% and equal to 36.5% of revenues (36.7% of revenues in the third quarter of 2014). When excluding the impact of the exchange rates from the quarters under comparison, EBITDA was up 9.3% and equal to about 37.5 percentage points of revenues.

In the third quarter of 2015, EBIT totalled 36,615 thousand euros, up 13.9 percentage points compared with 32,150 thousand euros in the third quarter of 2014 and equal to 29.7% of revenues (29.5% of revenues in 2014).

Financial income and expense

In the third quarter of 2015, net financial expense totalled 1,283 thousand euros compared with net financial income of 81 thousand euros in the same period of 2014.

The collection of interests accrued on past-due positions amounted to 83 thousand euros (596 thousand euros in the third quarter of 2014) and interests accrued on financial balances totalled 161 thousand euros (128 thousand euros in the same period of 2014).

The currency translation effect, which was negative by 819 thousand euros (positive by 1,054 thousand euros in the third quarter of 2014), related mainly to the Euro exchange rate of subsidiaries' financial balances that use currencies different from the Group's Parent Company currency.

Interests and other financial expense included 301 thousand euros in factoring transaction fees (333 thousand euros in the same period of 2014).

Profit before taxes and net profit

The third quarter of 2015 ended with a result before taxes of 35,332 thousand euros, up by 9.6% compared with 32,231 thousand euros in the third quarter of 2014, and equal to 28.7% of revenues (29.6% of revenues in 2014).

Income taxes amounted to 12,102 thousand euros, compared with 10,920 thousand euros in the third quarter of 2014. The tax rate increased to 34.3% in the third quarter of 2015 compared to a 33.9% tax rate in the third quarter of 2014, as a result of the computation of the Group's taxable profit across the different geographical areas in the periods under comparison.

Lastly, the net profit totalled 23,230 thousand euros, up by 9% compared with 21,311 thousand euros in the third quarter of 2014, and equal to 18.9% of revenues (down 0.6 percentage points) for the combined effect of the abovementioned elements.

OPERATING PERFORMANCE IN THE FIRST NINE MONTHS OF 2015

In the first nine of 2015, the DiaSorin Group reported **revenues of 368,376 thousand euros** (325,796 thousand euros in the first nine months of 2014). Revenues increased by 13.1% compared with 2014 (+5.7% at constant exchange rates). The exchange rate fluctuations had a positive impact of 23.9 million euros on the Group's revenues during the first nine months of 2015.

The first half of 2015 was characterized by the good performance of CLIA products, net of Vitamin D, up by 24.1% (18.5% at constant exchange rates) that offset the downward trend in sales of reagents used on RIA and ELISA technologies. Vitamin D sales grew by 10.6% at current exchange rates (-2% at constant exchange rates); instruments sales increased by 9.1% (3% at constant exchange rates).

The **gross profit** totalled **251,365 thousand euros**, up by 15.1% compared with 218,335 thousand euros in the same period in 2014. The ratio of gross profit to revenues was equal to 68.2% (67% in 2014). The increase is the net result of higher sales and different geographic and product mix during the periods under comparison.

EBITDA amounted to **136,424 thousand euros** (118,095 thousand euros in the same period of 2014) up by 15.5% or 18,329 thousand euros. EBITDA incidence to revenues increased from 36.2% in 2014 to 37% in the first nine months of 2015, following the lower incidence of operating expenses, the increase in gross profit and the exchange rate impact.

EBIT amounted to **111,692 thousand euros** (95,538 thousand euros in the first nine months of 2014), equal to 30.3% of revenues, up by 1 percentage point compared with 2014.

In the first nine months of 2015**, net financial expenses** totalled **2,523 thousand euros**, compared with net financial expenses of 455 thousand euros in the first nine months of 2014, due the currency translation effect.

Income taxes totalled **37,118 thousand euros** (33,799 thousand euros in 2014), the tax rate decreased to 34% from 35.5% in 2014, mainly as a result of lower amount of non-deductible taxes withheld on dividends the Group's Parent Company received from foreign subsidiaries and a lower tax rate in Italy following the introduction of regulatory amendments to help economic recovery.

The **net profit** for the first nine months of 2015 amounted to **72,051 thousand euros,** up by 10,767 thousand euros or 17.6% compared with the first nine months of 2014. The net profit was equal to 19.6% of revenues (18.8% in the first nine months of 2014).

CONSOLIDATED INCOME STATEMENT

(in thousands of euros)	**01.01-09.30 2015**	**as a% of revenues**	**01.01-09.30 2014**	**as a% of revenues**
Sales and service revenues	368,376	100.0%	325,796	100.0%
Cost of sales	(117,011)	31.8%	(107,461)	33.0%
Gross profit	**251,365**	**68.2%**	**218,335**	**67.0%**
Sales and marketing expenses	(72,219)	19.6%	(65,647)	20.1%
Research and development costs	(18,924)	5.1%	(18,553)	5.7%
General and administrative expenses	(40,720)	11.1%	(36,669)	11.3%
Total operating expenses	**(131,863)**	**35.8%**	**(120,869)**	**37.1%**
Other operating income (expense)	(7,810)	2.1%	(1,928)	0.6%
non- recurring amount	-	-	*(1,218)*	*0.4%*
EBIT	**111,692**	**30.3%**	**95,538**	**29.3%**
Net financial income (expense)	(2,523)	0.7%	(455)	0.1%
Profit before taxes	**109,169**	**29.6%**	**95,083**	**29.2%**
Income taxes	(37,118)	10.1%	(33,799)	10.4%
Net profit	**72,051**	**19.6%**	**61,284**	**18.8%**
EBITDA (1)	**136,424**	**37.0%**	**118,095**	**36.2%**

Unaudited data.

(1) The Company defines EBITDA as the “result from operations” before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group’s operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group’s operating performance. Because the composition of EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

Net revenues

In the first nine months of 2015, the DiaSorin Group generated **revenues** equal to **368,376 thousand euros** (325,796 thousand euros in the same period of 2014). A breakdown of revenues by geographic region of destination is as follows:

Breakdown of revenues by geographic region

(in thousands of euros)	**01.01 -09.30 2015**	**01.01 -09.30 2014**	**% Change at current exchange rates**	**% Change at constant exchange rates**
Europe and Africa	173,552	163,519	6.1%	5.0%
North America	96,139	76,272	26.0%	4.1%
Asia Pacific	69,422	53,718	29.2%	16.9%
Central and South America	29,263	32,287	-9.4%	-5.3%
Total	**368,376**	**325,796**	**13.1%**	**5.7%**





Europe and Africa

Europe and Africa sales region generated sales equal to 173,552 thousand euros, up 6.1 percentage points (+5% at constant exchange rates) compared with 163,519 thousand euros in 2014. Specifically:

i) growth in revenue in the Italian market (+1.8%), in a stable local market (+0.5%)[*], driven by Vitamin D and the upward trend of some CLIA products (particularly Hepatitis, Endocrinology, PCT and Stool testing);

ii) growth of 8.8 percentage points recorded in the German market (-1,.3% in the local market)[*], due to CLIA products and specifically to 1,25 Vitamin D, Stool testing and to the steady growth in Vitamin D sales;

iii) shrinking sales in the French market (-3.9%) entirely due to the Vitamin D performance, following the abovementioned healthcare reform. Net of these sales, the French subsidiary increased by 10.2 percentage points (Vitamin D equal to -35.9%)[*]. Sales of CLIA reagents

[*] EDMA latest data available

increased by 18.4 percentage points compared with the nine months of 2014, with the exception of Vitamin D;

iv) growth in all the countries of the area where the Group operates, with the sole exception of markets served through distributors' network that recorded a 4.8 percentage point decrease due to the socio-political tension in Russia.

North America

In the first nine months of 2015, the North America sales region reported revenues of 96,139 thousand euros, up by 4.1% in local currency (+26% at current exchange rates) compared with the same period of 2014 (76,272 thousand euros). This change reflects two opposing phenomena:

i) strong performance of CLIA ex Vitamin D specialties, with a gain of 43 percentage points, due to Infectious Diseases and Prenatal Screening that were strongly impacted by the agreement signed with LabCorp. Worth mentioning is the good performance of 1,25 Vitamin D test;

ii) stable Vitamin D sales (+0.7%) impacted by the agreement with Quest started in the second quarter of 2015.

Asia Pacific

In the first nine months of 2015, revenues of the Asia Pacific sales region amounted to 69,422 thousand euros, up by 29.2% (+16.9% at constant exchange rates) compared with the first nine months of 2014 (53,718 thousand euros). This is the net result of:

i) strong performance of the Chinese subsidiary, with a growth of 32.2 percentage points in local currency, on all CLIA products, that has more than offset the physiological decline in ELISA sales;

ii) lower sales in the Australian market (-3.6% in Australian dollars) due to lower Vitamin D sales volume also resulting from the reduction in reimbursement following the healthcare reform, partly offset by other CLIA sales. Net of Vitamin D, CLIA sales grew by 34.1%;

iii) higher sales generated through distributors in markets where the Group does not have a direct presence (+18.1% at current exchange rates) mainly due to Iran, Japan, South Korea and Saudi Arabia.

Central and South America

The Latin American sales region recorded revenues of 29,263 thousand euros in the first nine months of 2015, down by 9.4% (-5.3% at constant exchange rates) compared with 32,287 thousand euros in the same period of 2014.This change is mainly attributable to:

i) shrinking sales of the Brazilian subsidiary (-14% in local currency) due to the overall macroeconomic crisis affecting the country and to disruptions in some important local distributors;

ii) increased sales of the Mexican subsidiary (+0.8% in local currency) compared with the first nine months of 2014. Good performance of CLIA products, particularly in the Infectious Diseases panel;

iii) positive performance of the distributors' network in countries where the Group does not have a direct presence (+11% compared with the first nine months of 2014).

Breakdown of revenues by technology

% of revenues contributed	01.01 - 09.30 2015	01.01 - 09.30 2014
CLIA TESTS	74.5%	70.7%
ELISA TESTS	12.0%	14.4%
INSTRUMENTS SALES AND OTHER REVENUES	11.3%	11.7%
RIA TESTS	1.4%	2.5%
MOLECULAR DIAGNOSTICS	0.8%	0.7%
Total	**100.0%**	**100.0%**





The following provides the main elements of revenues by technology:

i) growth of 24.1% (18.5% at constant exchange rates) in CLIA sales, net of Vitamin D, mainly as a result of the successful LIAISON XL platform and of the new products launched on the market, particularly1,25 Vitamin D and Infectious Diseases, Hepatitis and Stool testing panels;

ii) trend in Vitamin D sales (+10.6% at current exchange rates, -2% at constant exchange rates), affected by the price reduction, partially offset by rising volumes driven by the agreement signed with Quest in the U.S. Noteworthy is the growth in sales carried out in Italy and Germany, the reduction of volumes sold in France and Australia resulting from the recent healthcare reform and a general downturn in the Brazilian market compared with the first nine months of 2014;

iii) increase of 9.1% (3% at constant exchange rates) in instruments and consumable sales, mainly in the Asian market;

iv) increase in the installed base: 360 new instruments have been placed in the first nine months of 2015, for a total of 6,232 installed units. LIAISON XL new installations amounted to 479, out of which 40 in the validation phase at customers' facilities.

Operating performance

The gross profit totalled 251,365 thousand euros, up 15.1% compared with 218,335 thousand euros in the same period of 2014; the ratio of gross profit to revenues increased to 68.2%, from 67% in 2014, mainly as a result of higher sales and a different sales mix (geography and product) of the periods under comparison.

Operating expenses totalled 131,863 thousand euros, up 9.1 percentage points compared with the same period of 2014 (120,869 thousand euros): their ratio to total revenues decreased from 37.1% to 35.8%. The change was negatively impacted by the exchange rate fluctuations (operating expenses amounted to 125.5 million euros at constant exchange rates, up 3.8 percentage points). This is the net result of the increase in sales and marketing expenses, costs for technical assistance to support the growing number of the installed base as well as general and administrative expenses.

Sales and marketing expenses amounted to 72,219 thousand euros, an increase of 6,572 thousand euros or 10% compared with 2014 (65,647 thousand euros). In addition to the costs incurred to support the sale force, this item includes marketing costs incurred to promote and distribute DiaSorin products and the cost of the technical support offered together with the Group-owned equipment provided to customers under gratuitous loan contracts. Higher sales and marketing expenses are related to the exchange rate effects, together with an increase in business volumes: their ratio to revenues decreased from 20.1% to 19.6%.

Research and development costs, equal to 18,924 thousand euros, are in line with costs recorded in 2014: their ratio to total revenues equal to 5.1 percentage points as against 5.7 percentage points in the first nine months of 2014.

General and administrative expenses amounted to 40,720 thousand euro: their ratio to total revenues equal to 11.1 percentage points (in line with 2014).

Other operating expenses equal to 7,810 thousand euros (1,928 thousand euros in 2014) include 1,465 thousand euros in tax charges (1,261 thousand euros in the first nine months of 2014) and 2,827 thousand euros in additions to the allowances for doubtful accounts. This item includes 3,015 thousand euros of negative translation adjustment on commercial items (a positive translation adjustment of 1,140 thousand euros positive in 2014), arising from the exchange rates fluctuation in the quarters under comparison.

In the first nine months of 2015, EBITDA amounted to 136,424 thousand euros, up by 15.5% compared with 118,095 thousand euros in 2014 and equal to 37% of revenues, up by 0.8 percentage points (36.2% of revenues in 2014). When excluding the impact of the exchange rates from the periods under comparison, EBITDA was up 6.7% and equal to about 36.6 percentage points of revenues.

In the first nine months of 2015, EBIT totalled 111,692 thousand euros, up by 16.9% compared with 95,538 thousand euros in 2014 and equal to 30.3% of revenues, up 1 percentage point compared with the same period last year.

Financial income and expense

In the first nine months of 2015, net financial expense amounted to 2,523 thousand euros compared with net financial expense of 455 thousand euros in the same period in 2014.

The collection of interests accrued on past-due positions amounted to 900 thousand euros in the first nine months of 2015 (801 thousand euros in the same period of 2014) and interests accrued on financial balances totalled 524 thousand euros (550 thousand euros in 2014).

The currency translation effect on other financial balances, which was negative by 1,734 thousand euros (positive by 863 thousand euros in the first nine months of 2014) include 456 thousand euros in expenses from changes in subsidiaries' financial balances that use currencies different from the Group's Parent Company currency (income of 1,776 thousand euros in the first nine months of 2014), and a loss of 1,278 thousand euros for the closure of financial instruments (expense of 913 thousand euros in 2014).

Interests and other financial expense for the period included 760 thousand euros in factoring transaction fees (970 thousand euros thousand euros in the same period in 2014).

Profit before taxes and net profit

The first nine months of of 2015 ended with a result before taxes of 109,169 thousand euros, up 14.8% compared with 95,083 thousand euros in the first nine months of 2014, equal to 29.6% of revenues (29.2% of revenues in 2014).

Income taxes amounted to 37,118 thousand euros compared with 33,799 thousand euros in 2014. The tax rate decreased from 35.5% in the first nine months of 2014 to 34 % in the third quarter of 2015, due mainly to lower amount of non-deductible taxes withheld on dividends the Group's Parent Company received from foreign subsidiaries and a lower tax rate in Italy following the introduction of regulatory amendments to help economic recovery.

Finally, the net profit for the first none months of 2015 totalled 72,051 thousand euros, up 17.6% compared with 61,284 thousand euros in 2014, and equal to 19.6% of revenues (18.8% of revenues in 2014) for the combined effect of the abovementioned elements.

STATEMENT OF FINANCIAL POSITION OF THE GROUP AT SEPTEMBER 30, 2015

A condensed statement of financial position of the Group at September 30, 2015 is provided below:

(in thousands of euros)	**09/30/2015**	**12/31/2014**
Intangible assets	116,510	116,950
Property, plant and equipment	73,750	72,207
Other non-current assets	22,411	25,584
Net working capital	145,881	142,281
Other non-current liabilities	(38,238)	(39,791)
Net invested capital	**320,314**	**317,231**
Net financial position	**231,868**	**166,342**
Shareholders' equity	**552,182**	**483,573**

Non-current assets decreased to 212,671 thousand euros at September 30, 2015 from 214,741 thousand euros at December 31, 2014 as a results of the exchange rates fluctuations.

A breakdown of net working capital is provided below:

(in thousands of euros)	**09/30/2015**	**12/31/2014**	**Change**
Trade receivables	105,045	109,521	(4,476)
Ending inventories	106,163	101,320	4,843
Trade payables	(35,106)	(39,311)	4,205
Other current assets/liabilities (1)	(30,221)	(29,249)	(972)
Net working capital	**145,881**	**142,281**	**3,600**

(1) Other current assets/liabilities is defined as the algebraic sum of receivables and payables other than financial and commercial items.

Net working capital increased by 3,600 thousand euros in the first nine months of 2015, following an increase in inventories.
The increase of 4,843 thousand euros in ending inventories compared with December 31, 2014 (out of which 1 million euros relating to the exchange rate) is due to the growth in manufacturing volumes to support higher revenues.

A condensed net financial position schedule is shown below:

(in thousands of euros)	**09/30/2015**	**12/31/2014**
Cash and cash equivalents	176,509	144,855
Liquid assets (a)	**176,509**	**144,855**
Other current financial assets (b)	**57,581**	**24,963**
Current bank debt	(2,222)	(3,007)
Other current financial liabilities	-	(259)
Current indebtedness (c)	**(2,222)**	**(3,266)**
Net current financial assets (d)=(a)+(b)+(c)	**231,868**	**166,552**
Non-current bank debt	-	(210)
Non-current indebtedness (e)	**-**	**(210)**
Net financial position (f)=(d)+(e)	**231,868**	**166,342**

At September 30, 2015, the net consolidated financial position was positive by 231,868 thousand euros, for an increase of 65,526 thousand euros compared with December 31, 2014, as a result of the strong cash flow generated from operating activities in the first nine months of 2015 and the sale of treasury shares due to the exercise of some tranches of the 2010 Stock Option Plan.

Shareholders' equity, which totalled 552,182 thousand euros at September 30, 2015 (483,573 thousand euros at December 31, 2014) includes treasury shares valued at 26,631 thousand euros.

ANALYSIS OF CONSOLIDATED CASH FLOWS

A schedule showing a condensed consolidated statement of cash flows, followed by a review of the main statement items and of the changes that occurred compared with the corresponding period in 2014, is provided below:

(in thousands of euros)	**01.01-09.30 2015**	**01.01-09.30 2014**	**3rd quarter 2015**	**3rd quarter 2014**
Cash and cash equivalents at beginning of period	**144,855**	**105,110**	**141,626**	**88,717**
Net cash from operating activities	96,370	91,885	40,619	39,015
Cash used for investing activities	(21,624)	(21,017)	(5,390)	(6,786)
Cash used for financing activities	(12,072)	(30,220)	674	3,054
Acquisitions of subsidiaries and business operations	(1,020)	-	(1,020)	-
Change in net cash before investments in financial assets	***61,654***	***40,648***	***34,883***	***35,283***
Investments in financial assets	(30,000)	(21,758)	-	-
Change in net cash	***31,654***	***18,890***	***34,883***	***35,283***
Cash and cash equivalents at end of period	**176,509**	**124,000**	**176,509**	**124,000**

The cash flow from operating activities amounted to 40,619 thousand euros in the third quarter of 2015, compared with 39,015 thousand euros in the third quarter of 2014. The cash generation from operating activities was higher than in 2014, as this item was offset by a greater absorption of the working capital.
Tax payments totalled 9,707 thousand euros in the third quarter of 2015 (7,159 thousand euros in the third quarter of 2014) consisting mainly of the US subsidiary's income taxes.

Investing activities absorbed cash totalling 5,390 thousand euros, compared with 6,786 thousand euros in the third quarter of 2014.

Net cash used for financing activities amounted to 674 thousand euros (3,054 thousand euros in the same period of 2014). The positive effect of the exchange rate fluctuations related to commercial items had an impact of 706 thousand euros, and more specifically the Group's cash expressed in U.S. dollars available as of September 30, 2015 (3,384 thousand euros in the third quarter of 2014).

Investments in subsidiaries concern assets DiaSorin Poland acquired from local distributor.

The cash flow from operating activities amounted to 96,370 thousand euros in the first nine months of 2015, as against 91,885 thousand euros in the first nine months of 2014. The cash generation from operating activities was higher compared with the first nine months of 2014, as it was offset by dynamics in working capital that recorded a downward trend following the payments of amounts owed to employees for the functional reorganization of some company areas in Italy that occurred at the end of 2014. It should be noted that the first nine months of 2014 profited from the collection of past-due positions the Spanish subsidiary owed by public entities.

Tax payments totalled 33,456 thousand euros (29,064 thousand euros in the first nine months of 2014), consisting mainly of the Group's Parent company's and the U.S. and German subsidiaries' income taxes.

Net cash used in investing activities totalled 21,624 thousand euros, compared with 21,017 thousand euros in the first nine of 2014. Capital expenditures for medical equipment amounted to 14,599 thousand euros, in line with the same period of 2014, when capital expenditures for medical equipment totalled 14,628 thousand euros. In addition, development costs of 1,285 thousand euros were capitalized in the first nine of 2015, as against development costs of 1,047 thousand euros in the same period of 2014.

The free cash flow increased to 74,768 thousand euros from 71,158 thousand euros in the first nine months of 2014.

The net cash used in financing activities totalled 12,072 thousand euros in the first nine months of 2015 (30,220 thousand euros in the same period in 2014). It was used mainly for dividend payment amounting to 32,936 thousand euros (29,919 thousand euros in 2014), offset by 17,162 thousand euros for the sale of treasure shares following the exercise of some tranches of the 2010 Stock Option Plan. The first nine months of 2015 recorded positive translation adjustment of 4,081 thousand euros on liquid assets at September 30, 2015, resulting from the revaluation of the currencies in which the Group operates vis-à-vis the Euro, particularly with regard to the US Dollar.

In the first nine months of 2015, the Group Parent Company opened a term deposit exceeding three months, for an amount equal to 30 million euros as against 21,758 thousand euros (USD 30 million) in investments in term deposits the U.S. subsidiary opened in 2014.

At September 30, 2015, available liquid assets held by the Group totalled 176,509 thousand euros, with an increase of 31,654 thousand euros compared with December 31, 2014.

OTHER INFORMATION

The Group had 1,654 employees at September 30, 2015 (1,620 employees at December 31,2014).

TRANSACTIONS WITH RELATED PARTIES

In the normal course of business, DiaSorin S.p.A. engages on a regular basis in commercial and financial transactions with its subsidiaries, which are also Group companies. These transactions, which are part of the Group's regular operations and are executed on standard market terms, consist of the supply of goods and services, including administrative, information technology, personnel management, technical support and consulting services, which produce receivables and payables at the end of the year, and financing and cash management transactions, which produce income and expenses.

These transactions are eliminated in the consolidation process and, consequently, are not discussed in this section of this Report.

The Group awards additional benefits to several eligible employees of DiaSorin S.p.A. and other Group companies through a stock option plan. The costs incurred in connection with this plan totalled 933 thousand euros in the first nine months of 2015 (345 thousand euros in 2014) and costs amounting to 313 thousand euros in the third quarter of 2015 (192 thousand euros in the same period in 2014).

The compensation payable to the key management and strategic management is consistent with standard market terms for compensation offered to employees with a similar status.

SIGNIFICANT EVENTS OCCURRING AFTER SEPTEMBER 30, 2015 AND BUSINESS OUTLOOK

No significant events occurred after September 30, 2015.

Consistent with the positive sales trend, the improvement in gross profit and the lower incidence of operating expenses on revenues, management believes that it should revise upward its earlier expectations for the current year and projects:

- Revenues: growth above 5% at constant exchange rates compared with 2014 (previous growth range between +4% and +5% at constant exchange rates);
- EBITDA: increase of the growth range between +6% and +7% at constant exchange rates compared with 2014 (previous growth range between +4% and +5% at constant exchange rates).
- LIAISON/LIAISON XL installed base: ca. 550.

CONSOLIDATED FINANCIAL STATEMENTS OF THE DIASORIN GROUP AT SEPTEMBER 30, 2015 AND ACCOMPANYING NOTES

CONSOLIDATED INCOME STATEMENT

(in thousands of euros)	notes	3rd quarter		01.01 - 09.30	
		2015	**2014**	**2015**	**2014**
Net revenues	(1)	123,232	109,025	368,376	325,796
Cost of sales	(2)	(38,201)	(36,601)	(117,011)	(107,461)
Gross profit		**85,031**	**72,424**	**251,365**	**218,335**
Sales and marketing expenses	(3)	(23,496)	(21,592)	(72,219)	(65,647)
Research and development costs	(4)	(6,254)	(6,177)	(18,924)	(18,553)
General and administrative expenses	(5)	(13,728)	(12,377)	(40,720)	(36,669)
Other operating income (expenses)	(6)	(4,938)	(128)	(7,810)	(1,928)
non-recurring amount		-	-	-	*(1,218)*
EBIT		**36,615**	**32,150**	**111,692**	**95,538**
Net financial income/ (expense)	(7)	(1,283)	81	(2,523)	(455)
Profit before taxes		**35,332**	**32,231**	**109,169**	**95,083**
Taxes	(8)	(12,102)	(10,920)	(37,118)	(33,799)
Net profit for the period		**23,230**	**21,311**	**72,051**	**61,284**
Broken down as follows:					
- Parent Company shareholders' interests in net result		23,150	21,311	71,971	61,284
- Minority shareholders' interests in net result		80	-	80	-
Earnings per share (basic)	(9)	**0.42**	**0.40**	**1.31**	**1.13**
Earnings per share (diluted)	(9)	**0.42**	**0.40**	**1.31**	**1.13**

COMPREHENSIVE INCOME STATEMENT

(in thousands of euros)	3rd quarter 2015	3rd quarter 2014	01.01 - 09.30 2015	01.01 - 09.30 2014
Net profit for the period (A)	**23,230**	**21,311**	**72,051**	**61,284**
Other comprehensive gains/(losses) that will not be reclassified subsequently to gain/(loss) of the period:				
Gains/(losses) on remeasurement of defined benefit plans	122	(101)	309	(316)
Total other comprehensive gains/(losses) that will not be reclassified subsequently to gain/(loss) of the period (B1)	**122**	**(101)**	**309**	**(316)**
Other comprehensive gains/(losses) that will be reclassified subsequently to gain/loss of the period:				
Gains/(losses) on exchange differences on translating foreign operations	(3,137)	10,827	11,444	13,489
Gains/(losses) on net investment hedge	-	-	-	97
Total other comprehensive gains/(losses) that will be reclassified subsequently to gain/(loss) of the period (B2)	**(3,137)**	**10,827**	**11,444**	**13,586**
TOTAL OTHER COMPREHENSIVE GAINS/(LOSSES), NET OF TAX (B1) +(B2) =(B)	**(3,015)**	**10,726**	**11,753**	**13,270**
TOTAL COMPREHENSIVE GAINS/(LOSSES) (A)+(B)	**20,215**	**32,037**	**83,804**	**74,554**
Including:				
-amount attributable to Parent Company's shareholders	20,143	31,998	83,714	74,523
-amount attributable to minority interests	72	39	90	31

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(in thousands of euros)	**notes**	**09/30/2015**	**12/31/2014**
ASSETS			
Non-current assets			
Property, plant and equipment	(10)	73,750	72,207
Goodwill	(11)	67,971	67,703
Other intangibles	(11)	48,539	49,247
Equity investments	(12)	223	506
Deferred-tax assets	(13)	21,094	22,194
Other non-current assets	(14)	1,094	2,884
Total non-current assets		*212,671*	*214,741*
Current assets			
Inventories	(15)	106,163	101,320
Trade receivables	(16)	105,045	109,521
Other current assets	(17)	10,375	10,291
Other current financial assets	(18)	57,581	24,963
Cash and cash equivalents	(18)	176,509	144,855
Total current assets		*455,673*	*390,950*
TOTAL ASSETS		**668,344**	**605,691**

CONSOLIDATED STATEMENT OF FINANCIAL POSITION *(continued)*

(in thousands of euros)	**notes**	**09/30/2015**	**12/31/2014**
LIABILITIES AND SHAREHOLDERS' EQUITY			
Shareholders' equity			
Share capital	(19)	55,948	55,948
Treasury shares	(19)	(26,631)	(44,045)
Additional paid-in capital	(19)	18,155	18,155
Statutory reserve	(19)	11,190	11,190
Other reserves and retained earnings	(19)	421,255	358,047
Net profit for the period attributable to shareholders of the Parent Company		71,971	84,074
Shareholders' equity attributable to shareholders of the Parent Company		*551,888*	*483,369*
Other reserves and retained earnings attributable to minority interests		214	204
Net profit for the period attributable to minority interest		80	-
Shareholders' equity attributable to minority interests		*294*	*204*
Total Shareholders' equity		**552,182**	**483,573**
Non-current liabilities			
Long-term borrowings	(20)	-	210
Provisions for employee severance indemnities and other employee benefits	(21)	31,884	32,106
Deferred-tax liabilities	(13)	3,008	3,008
Other non-current liabilities	(22)	3,346	4,677
Total non-current liabilities		*38,238*	*40,001*
Current liabilities			
Trade payables	(23)	35,106	39,311
Other current liabilities	(24)	30,582	30,573
Income taxes payable	(25)	10,014	8,967
Current portion of long-term debt	(20)	2,222	3,007
Other financial liabilities	(20)	-	259
Total current liabilities		*77,924*	*82,117*
Total liabilities		**116,162**	**122,118**
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		**668,344**	**605,691**

CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands of euros)	3rd quarter		01.01 - 09.30	
	2015	**2014**	**2015**	**2014**
Cash flow from operating activities				
Net profit for the period	23,230	21,311	72,051	61,284
Adjustment for:				
- Income taxes	12,102	10,920	37,118	33,799
- Depreciation and amortization	8,411	7,868	24,732	22,557
- Financial expense/ (income)	1,283	(81)	2,523	455
- Additions to/ (Utilizations of) provisions for risk	1,237	545	1,935	1,086
- (Gains)/Losses on sales of non-current assets	55	51	116	54
- Additions to/ (Reversals of) provisions for employee severance indemnities	201	211	597	611
- Changes in shareholders' equity reserves:				
- Stock option reserve	313	192	933	345
- Cumulative translation adjustment from operating activities	3,459	1,248	3,497	420
- Change in other non current-assets/liabilities	(1,035)	(429)	(1,547)	(535)
Cash flow from operating activities before changes in working capital	**49,256**	**41,836**	**141,955**	**120,076**
(Increase)/Decrease in receivables included in working capital	5,350	7,169	3,457	9,143
(Increase)/Decrease in inventories	(951)	(3,415)	(4,249)	(6,762)
Increase/(Decrease) in trade payables	(7,154)	(1,015)	(7,230)	(690)
Increase)/Decrease in other current items	4,050	1,428	(4,085)	(528)
Cash from operating activities	**50,551**	**46,003**	**129,848**	**121,239**
Income taxes paid	(9,707)	(7,159)	(33,456)	(29,064)
Interest received (paid)	(225)	171	(22)	(290)
Net cash from operating activities	**40,619**	**39,015**	**96,370**	**91,885**
Investments in intangibles	(666)	(667)	(2,356)	(1,944)
Investments in property, plant and equipment	(5,205)	(6,465)	(20,395)	(20,329)
Investments in subsidiaries	-	(212)	(112)	(340)
Divestments of property, plant and equipment	481	558	1,239	1,596
Cash used in regular investing activities	**(5,390)**	**(6,786)**	**(21,624)**	**(21,017)**
Acquisitions of subsidiaries and business operations	(1,020)	-	(1,020)	-
Cash used in investing activities	**(6,410)**	**(6,786)**	**(22,644)**	**(21,017)**
(Redemptions)/Collections of loans and other liabilities	(272)	(330)	(379)	(4,050)
(Issuance)/Repayments of term deposit	-	-	(30,000)	(21,758)
(Purchase)/Sale of treasury shares	240	-	17,162	-
Dividends distribution	-	-	(32,936)	(29,919)
Foreign exchange translation differences	706	3,384	4,081	3,749
Cash used in financing activities	**674**	**3,054**	**(42,072)**	**(51,978)**
Change in net cash and cash equivalents	**34,883**	**35,283**	**31,654**	**18,890**
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	**141,626**	**88,717**	**144,855**	**105,110**
CASH AND CASH EQUIVALENTS AT END OF PERIOD	**176,509**	**124,000**	**176,509**	**124,000**

STATEMENT OF CHANGES IN CONSOLIDATED SHAREHOLDERS' EQUITY

(in thousands of euros)	**Share capital**	**Treasu-ry shares**	**Additio-nal paid-in capital**	**Statuto-ry reserve**	**Curren-cy transla-tion reserve**	**Stock option reserve**	**Reserve for treasury shares**	**Other reserves and retained earnings**	**Profit/ (loss) of the period**	**Group interest in share-holders' equity**	**Minority interest in share-holders' equity**	**Total interest in share-holders 'equity**
Shareholders' equity at 12/31/2013	**55,948**	**(44,882)**	**18,155**	**11,181**	**(6,097)**	**4,222**	**44,882**	**247,516**	**83,028**	**413,953**	**182**	**414,135**
Appropriation of previous year's profit	-	-	-	9	-	-	-	83,019	(83,028)	-	-	-
Dividend distribution	-	-	-	-	-	-	-	(29,919)	-	**(29,919)**	**-**	**(29,919)**
Stock options and other changes	-	-	-	-	-	345	-	-	-	**345**	**-**	**345**
Translation adjustment	-	-	-	-	13,458	-	-	-	-	**13,458**	**31**	**13,489**
Gains/(losses) on remeasurement of defined benefit plans, net of tax	-	-	-	-	-	-	-	(316)	-	**(316)**	**-**	**(316)**
Gains/(losses) on net investment hedge, net of tax	-	-	-	-	97	-	-	-	-	**97**	**-**	**97**
Net profit for the period	-	-	-	-	-	-	-	-	61,284	**61,284**	**-**	**61,284**
Shareholders' equity at 9/30/2014	**55,948**	**(44,882)**	**18,155**	**11,190**	**7,458**	**4,567**	**44,882**	**300,300**	**61,284**	**458,902**	**213**	**459,115**
Shareholders' equity at 12/31/2014	**55,948**	**(44,045)**	**18,155**	**11,190**	**12,304**	**4,781**	**44,045**	**296,917**	**84,074**	**483,369**	**204**	**483,573**
Appropriation of previous year's profit	-	-	-	-	-	-	-	84,074	(84,074)	-	-	-
Dividend distribution	-	-	-	-	-	-	-	(32,936)	-	**(32,936)**		**(32,936)**
Stock options and other changes	-	-	-	-	-	(3,133)	-	3,712	-	**579**	**-**	**579**
Translation adjustment	-	-	-	-	11,434	-	-	-	-	**11,434**	**10**	**11,444**
Sale of treasury shares	-	17,414	-	-	-	-	(17,414)	17,162	-	**17,162**	**-**	**17,162**
Gains/(losses) on remeasurement of defined benefit plans, net of tax	-	-	-	-	-	-	-	309	-	**309**	**-**	**309**
Net profit for the period	-	-	-	-	-	-	-	-	71,971	**71,971**	**80**	**72,051**
Shareholders' equity at 9/30/2015	**55,948**	**(26,631)**	**18,155**	**11,190**	**23,738**	**1,648**	**26,631**	**369,238**	**71,971**	**551,888**	**294**	**552,182**

NOTES TO THE CONSOLIDATED QUARTERLY REPORT AT SEPTEMBER 30, 2015 AND SEPTEMBER 30, 2014

GENERAL INFORMATION AND SCOPE OF CONSOLIDATION

General information

The DiaSorin Group specializes in the development, manufacture and distribution of products in the immunodiagnostics and molecular diagnostics tests. The Group's Parent Company, DiaSorin S.p.A., has its headquarters on Via Crescentino (no building number), in Saluggia (VC).

Principles for the preparation of the interim report on operations

This quarterly report was prepared in compliance with the International Financial Reporting Standards ("IFRSs"), as issued by the International Accounting Standards Board ("IASB") and adopted by the European Union. The designation IFRSs also includes the International Accounting Standards ("IASs") that are still in effect and all of the interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

This quarterly report was prepared in accordance with the requirements of the relevant international accounting standard (IAS 34 – Interim Financial Reporting).
These notes provide information in summary form, in order to avoid duplicating information published previously, as required by IAS 34. Specifically, these notes discuss only those components of the income statement and balance sheet the composition or change in amount of which require comment (due to the amount involved or the type of transaction or because an unusual transaction is involved) in order to understand the Group's operating performance, financial performance and financial position.

When preparing interim financial statements, management is required to develop estimates and assumptions that affect the amounts shown for revenues, expenses, assets and liabilities in the financial statements and the disclosures provided with regard to contingent assets and liabilities on the date of the interim financial statements. If such estimates and assumptions, which were based on management's best projections, should differ from actual events, they will be modified appropriately when the relevant events produce the abovementioned differences.

As a rule, certain valuation processes, particularly the most complex ones such as determining whether the value of non-current assets has been impaired, are carried out fully only in connection with the preparation of the annual financial statements, when all the necessary information is available, except when there are impairment indicators that require an immediate evaluation of any impairment losses that may have occurred.

The income tax liability is recognized using the best estimate of the weighted average tax rate projected for the entire year.

In this consolidated Quarterly Report, all amounts are in thousands of euros unless otherwise stated.

This quarterly report was not audited.

Financial statement presentation formats

The financial statements are presented in accordance with the following formats:

- in the income statement, costs are broken down by function. This income statement format, also known as a “cost of sales” income statement, is more representative of the Group’s business than a presentation with expenses broken down by nature because it is consistent with internal reporting and business management methods and with international practice in the diagnostic industry;
- in the statement of financial position, current and non-current assets liabilities are shown separately;
- the statement of cash flows is presented in accordance with the indirect method.

Scope of consolidation

This consolidated quarterly report includes the financial statements of DiaSorin S.p.A., the Group’s Parent Company, and those of its subsidiaries.

Subsidiaries are those companies over which the Group exercises control pursuant to IFRS 10, that is when the Group is exposed, or has right, to variable returns from its involvement with the subsidiary and, meanwhile, has the ability to affect those returns through its power over the subsidiary.

Subsidiaries are consolidated line by line from the date the Group obtains control until the moment when control ceases to exist.

Dormant subsidiaries and subsidiaries that generate an insignificant volume of business are not consolidated. Their impact on the Group’s total assets and liabilities, financial position and bottom-line result is not material.

The Group has neither subsidiaries with significant minority interest, nor unconsolidated structured entities and it is not subject to significant restrictions concerning interest in subsidiaries.

With reference to changes occurred in the scope of consolidation, on February 26, 2015 the Group established DiaSorin Poland, located in Warsaw. The entire equity investment held in DiaSorin Poland by the Group’s Parent company was consolidated as of July 1, 2015.

The following table lists the direct and indirect interest of DiaSorin S.p.A. as of September 30, 2015 and December 31, 2014:

		At September 30, 2015		At December 31, 2014	
Company	**Head office location**	**% interest held by the Group**	**% minority interest**	**% interest held by the Group**	**% minority interest**
Direct interest					
DiaSorin S.A/N.V.	Belgium	100%	-	100%	-
DiaSorin Ltda	Brazil	100%	-	100%	-
DiaSorin S.A.	France	100%	-	100%	-
DiaSorin Iberia S.A.	Spain	100%	-	100%	-
DiaSorin Ltd	UK	100%	-	100%	-
DiaSorin Inc.	USA	100%	-	100%	-
DiaSorin Mexico S.A de C.V.	Mexico	100%	-	100%	-
DiaSorin Deutschland GmbH	Germany	100%	-	100%	-
DiaSorin AB	Sweden	100%	-	100%	-
DiaSorin Ltd	Israel	100%	-	100%	-
DiaSorin Austria GmbH	Austria	100%	-	100%	-
DiaSorin Czech s.r.o.	Czech Republic	100%	-	100%	-
DiaSorin Diagnostics Ireland Limited	Ireland	100%	-	100%	-
DiaSorin South Africa (PTY) Ltd	South Africa	100%	-	100%	-
DiaSorin Australia (Pty) Ltd	Australia	100%	-	100%	-
DiaSorin Ltd	China	80%	20%	80%	20%
DiaSorin Switzerland AG	Switzerland	100%	-	100%	-
DiaSorin Poland sp. z o.o.	Poland	100%	-	-	-
Indirect interest		100%	-	100%	-
DiaSorin Canada Inc	Canada	100%	-	100%	-
DiaSorin Ireland Limited	Ireland	100%	-	100%	-
DiaSorin I.N.UK Limited	Ireland	100%	-	100%	-

A list of the subsidiaries, complete with information about head office locations and the percentage interest held by the Group, is provided in Annex I.

New accounting principles

On 20 May 2013, the IASB issued the IFRIC Interpretation 21 - *Levies*, an interpretation of *IAS 37 - Provisions, Contingent Liabilities and Contingent Assets*. IFRIC 21 addresses when an entity should recognize a liability to pay levies imposed by government, other than taxes that are within the scope of other standards (i.e. IAS 12 – *Income Taxes*). IAS 37 sets out criteria for the recognition of a liability, one of which is the requirement for the entity to have a present obligation as a result of a past event (known as an obligating event). The interpretation clarifies that the obligating event that gives rise to a liability to pay a levy is the activity described in the relevant legislation that triggers the payment of the levy. The principle shall be applied retrospectively for the financial years starting at the latest from 17 June 2014 or later.

Accounting principles and amendments not yet applicable and not adopted early by the Group

On November 21, 2013, the IASB issued narrow scope amendments to IAS 19 – Employee Benefits entitled "Defined Benefit Plans: Employee Contributions". The amendments are intended to simplify the accounting treatment for contributions to defined benefit plans from employees or third parties. Amendments shall be applied at the latest from 1 February 2015 or later.

On December 12, 2013 the IASB issued the Annual Improvements to IFRSs 2010–2012 Cycle and Annual Improvements to IFRSs 2011–2013 Cycle. The most important topics addressed in these amendments are, among others, the definition of vesting conditions in IFRS 2 – Share based payment, the disclosure on judgment used in the aggregation of operating segments in IFRS 8 – Operating Segments, the identification and disclosure of a related party transaction that arises when a management entity provides key management personnel service to a reporting entity in IAS 24 – Related Party disclosures, the extension of the exclusion from the scope of IFRS 3 – Business Combinations to all types of joint arrangements (as required by IFRS 11- Joint arrangements) and to clarify the application of certain exceptions in IFRS 13 – Fair value Measurement. Amendments shall be applied at the latest from 1 February 2015 or later.

At the date of these financial statements, the competent bodies of the European Union have not yet completed the approval process required for the adoption of the following accounting principles and amendments:

- On May 6, 2014, the IASB issued amendments to IFRS 11 – Joint arrangements: Accounting for acquisitions of interests in joint operations, clarifying the accounting for acquisitions of an interest in a joint operation that constitutes a business. The amendments are effective, retrospectively, for annual periods beginning on or after 1 January 2016 with earlier application permitted.

- On May 12, 2014, the IASB issued an amendment to IAS 16 Property, Plant and Equipment and to IAS 38 Intangible Assets – "Clarification of acceptable methods of depreciation and amortization". Amendments to IAS 16 establish that a revenue-based amortization method is inappropriate. The IASB has clarified that revenue generated by an activity that includes the use of an asset generally reflects factors other than the consumption of the economic benefits embodied in the asset. Amendments to IAS 38 introduce a rebuttable presumption to clarify that a revenue-based amortization method is inappropriate for the same reasons established by the amendments as required by IAS 16. This presumption, however, can be rebutted in certain limited circumstances. These amendments are effective for annual periods beginning from January 1, 2016, with early application permitted.

- On May 28, 2014, the IASB issued "IFRS 15 Revenue from contracts with customers" that will supersede IAS 18 Revenue and IAS 11 Construction Contracts, as well as the interpretations of IFRIC 13 Customer Loyalty Programs, IFRIC 15 Agreements for the Construction of Real Estate, IFRIC 18 Transfers of Assets from Customers and SIC 31 Revenues-Barter Transactions Involving Advertising Services. The new revenue model will apply to all contracts with customers except for those within the scope of IAS/IFRS concerning leases, insurance contracts and financial instruments. The core principle of the revenue recognition standard is delivered as follows:

    - identify the contract with the customer;
    - identify the performance obligations in the contract;
    - determine the transaction price;

- allocate the transaction price to the performance obligations in the contracts;
- recognize revenue when (or as) the entity satisfies a performance obligation.

The principle is effective for annual periods beginning from January 1, 2018, with early application permitted.

- On July 24, 2014, the IASB issued the final version of IFRS 9- Financial Instruments, bringing together the Classification and measurement, Impairment and Hedge accounting phases of the IASB's project to replace IAS 39. The new principle replaces the previous versions of IFRS 9 and is effective for annual periods beginning on or after 1 January 2018.

- On August 12, 2014, the IASB issued amendments to IAS 27 - Equity Method in Separate Financial Statements. The amendments reinstate the equity method as an accounting option for investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. The amendments are effective for annual periods beginning on or after 1 January 2016, with earlier application being permitted.

- On September 11, 2014, the IASB issued amendments to IFRS 10 and IAS 28 Sales or Contribution of Assets between an Investor and its Associate or Joint Venture. The amendments set out that on a sale/ contribution of assets or subsidiary to a joint venture or associate the extent of any gain or loss recognized in the transferor/transferring company depends on whether the transferred/conferred assets or subsidiary constitute a business. The amendments are effective for annual periods beginning on or after 1 January 2016, with earlier application being permitted.
- On September 25, 2014, the IASB issued "Annual Improvements to IFRSs: 2012-2014 Cycle", a series of amendments to the following four standards: IAS 19 (to clarify that the high quality corporate bonds used in estimating the discount rate for post-employment benefits should be denominated in the same currency as the benefits to be paid), IFRS 5 (to provide specific guidance for cases in which an entity reclassifies an asset or a disposal group from held for sale to held for distribution or vice versa and cases in which held-for-distribution accounting is discontinued) IFRS 7 (to add additional guidance to clarify whether a servicing contract is continuing involvement in a transferred asset for the purpose of determining the disclosures required) and IAS 34 (to clarify that certain disclosures, if they are not included in the notes to interim financial statements, may be disclosed "elsewhere in the interim financial report"). The amendments are effective for annual periods beginning on or after 1 January 2016.

- On December 18, 2014 the IASB issued amendments to IAS 1 - Disclosure Initiative to clarify perceived impediments to preparers exercising their judgment in presenting their financial reports. Specifically, the amendments concern how line items can be aggregated or disaggregated in the statement of financial position and in the notes on the basis of their materiality. Lastly, the amendments give guidance on use of subtotals in the financial statements tables. The amendments are effective for annual periods beginning on or after 1 January 2016.

The Group will comply with these new standards, amendments and interpretations based on their relevant effective dates, when endorsed by the European Union.

Other information
Information about significant events occurring after September 30, 2015, the Group's business outlook and its transactions with related parties is provided in separate sections of this Quarterly Report.

The table below shows the exchange rates used to translate amounts reported by companies that operate outside the euro zone:

Currency	**Average exchange rates**				**Exchange rates at**		
	01.01 - 09.30 2015	**01.01 - 09.30 2014**	**3rd quarter 2015**	**3rd quarter 2014**	**09/30/2015**	**09/30/2014**	**12/31/2014**
U.S. dollar	1.1144	1.3549	1.1117	1.3256	1.1203	1.2583	1.2141
Brazilian real	3.5257	3.1028	3.9340	3.0137	4.4808	3.0821	3.2207
British pound	0.7271	0.8118	0.7173	0.7938	0.7385	0.7773	0.7789
Swedish kronor	9.3709	9.0405	9.4293	9.2052	9.4083	9.1465	9.3930
Swiss franc	1.0621	1.2180	1.0723	1.2115	1.0915	1.2063	1.2024
Czech koruna	27.3547	27.5043	27.0755	27.6189	27.1870	27.5000	27.7350
Canadian dollar	1.4038	1.4819	1.4540	1.4422	1.5034	1.4058	1.4063
Mexican peso	17.3653	17.7720	18.2680	17.3879	18.9768	16.9977	17.8679
Israeli shekel	4.3344	4.7322	4.2793	4.6593	4.4001	4.6474	4.7200
Chinese yuan	6.9641	8.3544	7.0083	8.1734	7.1206	7.7262	7.5358
Australian dollar	1.4631	1.4760	1.5331	1.4326	1.5939	1.4442	1.4829
South African rand	13.7010	14.5356	14.4516	14.2700	15.4984	14.2606	14.0353
Norwegian krone	8.8174	8.2761	9.1378	8.2754	9.5245	8.1190	9.0420
Polish zloty	4.1571	4.1752	4.1877	4.1747	4.2448	4.1776	4.2732

OPERATING SEGMENTS

In accordance with IFRS 8, the Group designated the geographic regions where it operates as its operating segments.

The Group’s organization and internal management structure and its reporting system are segmented as follows: Italy and U.K. branch, Europe (Germany, France, Belgium and the Netherlands, Spain and Portugal, Ireland, Austria, Great Britain, Scandinavia, Czech Republic, Switzerland and Poland), North America (United States and Canada) and Rest of the World (Brazil, Mexico, Israel, China, Australia and South Africa).

The Group is characterized by an organization of its commercial structure by geographic regions, which was adopted to accommodate the Group’s geographic expansion and strategic initiatives. The logic of this new organization reflects the destination of the Group’s sales, dividing the sales areas into four regions: Europe and Africa, North America, Central and South America, Asia Pacific and China.

As a result, the communication of the financial data of the DiaSorin Group to the financial markets and the investing public is being changed to show revenue data aligned with its organization by regions.

The tables on the following pages show the Group’s operating and financial data broken down by geographic region. A listing of revenues by customer location is provided in the table included in the corresponding Note that shows a breakdown of sales and service revenues by geographic region.

The table that follows shows no unallocated common costs. This is because each country (hence, each segment) has a complete organization (commercial, technical support and administrative) capable of operating independently. In addition, the Italy segment charges quarterly the other segments for costs the Corporate division faces at the central level for assets in favour of the Group’s companies.

Eliminations refer primarily to inter-segment margins that are eliminated at consolidation. Specifically, the elimination of the margin earned by the Italy segment through the sale of equipment to other segments is carried out both at the result and investment levels. The margin generated by products sold by the manufacturing locations to the commercial branches but not yet sold to outsiders is eliminated only at the result level.

Segment assets include all operating items (non-current assets, receivables and inventory) but not tax-related items (deferred-tax assets) and financial assets, which are shown at the Group level.
The same approach was used for segment liabilities, which include operating items (mainly trade payables and amounts owed to employees) but do not include financial and tax liabilities or shareholders’ equity, which are shown at the Group level.

	ITALY		EUROPE		NORTH AMERICA		REST OF THE WORLD		ELIMINATIONS		CONSOLIDATED	
(in thousands of euros)	01.01 – 09.30		01.01 - 09.30		01.01 - 09.30		01.01 - 09.30		01.01 - 09.30		01.01 - 09.30	
	2015	2014	2015	2014	2015	2014	2015	2014	2015	2014	2015	2014
INCOME STATEMENT												
Revenues from customers	95,010	89,210	104,255	95,028	100,237	80,103	68,874	61,455	-	-	368,376	325,796
Inter-segment revenues	115,367	98,333	19,221	17,529	29,292	21,502	1,889	2,041	(165,769)	(139,405)	-	-
Total revenues	**210,377**	**187,543**	**123,476**	**112,557**	**129,529**	**101,605**	**70,763**	**63,496**	**(165,769)**	**(139,405)**	**368,376**	**325,796**
Segment EBIT	**42,327**	**39,124**	**13,734**	**8,183**	**60,209**	**47,229**	**(743)**	**1,298**	**(3,835)**	**(296)**	**111,692**	**95,538**
Unallocated common costs	-	-	-	-	-	-	-	-	-	-	-	-
Operating margin	-	-	-	-	-	-	-	-	-	-	**111,692**	**95,538**
Financial income/ (expense)	-	-	-	-	-	-	-	-	-	-	(2,523)	(455)
Result before taxes	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**109,169**	**95,083**
Income taxes	-	-	-	-	-	-	-	-	-	-	(37,118)	(33,799)
Net result	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**72,051**	**61,284**
OTHER INFORMATION												
Investments in intangibles	1,274	809	459	564	460	525	163	46	-	-	2,356	1,944
Invest. in prop. plant and equip.	7,416	6,180	4,856	6,222	6,526	4,446	4,766	6,168	(3,169)	(2,687)	20,395	20,329
Total investments	**8,690**	**6,989**	**5,315**	**6,786**	**6,986**	**4,971**	**4,929**	**6,214**	**(3,169)**	**(2,687)**	**22,751**	**22,273**
Amortization of intangibles	(2,901)	(2,848)	(2,360)	(2,268)	(433)	(447)	(488)	(501)	32	-	(6,150)	(6,064)
Depreciation of prop. plant and equip.	(6,237)	(5,783)	(6,004)	(5,583)	(5,073)	(3,919)	(3,896)	(3,601)	2,628	2,393	(18,582)	(16,493)
Total amortization and depreciation	**(9,138)**	**(8,631)**	**(8,364)**	**(7,851)**	**(5,506)**	**(4,366)**	**(4,384)**	**(4,102)**	**2,660**	**2,393**	**(24,732)**	**(22,557)**

	ITALY		EUROPE		NORTH AMERICA		REST OF THE WORLD		ELIMINATIONS		CONSOLIDATED	
(in thousands of euros)	09/30/2015	12/31/2014	09/30/2015	12/31/2014	09/30/2015	12/31/2014	09/30/2015	12/31/2014	09/30/2015	12/31/2014	09/30/2015	12/31/2014
STATEMENT OF FINANCIAL POSITION												
Segment assets	238,466	238,758	144,229	140,519	94,633	83,304	51,831	60,856	(116,222)	(110,264)	412,937	413,173
Unallocated assets	-	-	-	-	-	-	-	-	-	-	255,407	192,518
Total assets	**238,466**	**238,758**	**144,229**	**140,519**	**94,633**	**83,304**	**51,831**	**60,856**	**(116,222)**	**(110,264)**	**668,344**	**605,691**
Segment liabilities	50,472	61,823	63,110	58,460	14,407	14,902	35,328	30,892	(62,399)	(59,410)	100,918	106,667
Unallocated liabilities	-	-	-	-	-	-	-	-	-	-	15,244	15,451
Shareholders’ equity	-	-	-	-	-	-	-	-	-	-	552,182	483,573
Total liabilities and shareholders’ equity	**50,472**	**61,823**	**63,110**	**58,460**	**14,407**	**14,902**	**35,328**	**30,892**	**(62,399)**	**(59,410)**	**668,344**	**605,691**

	EUROPE AND AFRICA		NORTH AMERICA		ASIA PACIFIC		CENTRAL AND SOUTH AMERICA		CONSOLIDATED	
(in thousands of euros)	**01.01 – 09.30**		**01.01 - 09.30**		**01.01 - 09.30**		**01.01 - 09.30**		**01.01 - 09.30**	
	2015	**2014**	**2015**	**2014**	**2015**	**2014**	**2015**	**2014**	**2015**	**2014**
INCOME STATEMENT										
Revenues from customers	173,552	163,519	96,139	76,272	69,422	53,718	29,263	32,287	**368,376**	**325,796**

DESCRIPTION AND MAIN CHANGES

Consolidated income statement

1. Net revenues

In the third quarter of 2015, net revenues, which are generated mainly through the sale of diagnostic kits, totalled 123,232 thousand euros, up 13% compared with the third quarter of 2014 (109,025 thousand euros). Net revenues include 3,512 thousand euros for equipment rentals and technical support (1,980 thousand euros in the same period of 2014).

In the first nine months of 2015, net revenues amounted to 368,376 thousand euros, up 13.1 percentage points compared with the first nine months of 2014 (325,796 thousand euros) and include 7,942 thousand euros for equipment rentals and technical support (5,706 thousand euros in the same period of 2014).

2. Cost of sales

In the third quarter of 2015, the cost of sales amounted to 38,201 thousand euros compared with 36,601 thousand euros in the same period of 2014 and includes 2,161 thousand euros in royalty expense (1,638 thousand euros in the third quarter of 2014) and 2,279 thousand euros in costs incurred to distribute products to end costumers (2,116 thousand euros in 2014). This item also includes the depreciation of medical equipment held by customers, which amounted to 4,479 thousand euros (4,051 thousand euros in the same period of 2014).

At the end of the first nine months of 2015, the cost of sales totalled 117,011 thousand euros (107,461 thousand euros in the first nine months of 2014) and includes 5,988 thousand euros in royalty expense (4,831 thousand euros in 2014), and 6,550 thousand euros in distribution costs (6,505 thousand euros in 2014). The cost of sales consists also of the depreciation of medical equipment held by customers, equal to 13,229 thousand euros (11,728 thousand euros in 2014).

3. Sales and marketing expenses

Sales and marketing expenses totalled 23,496 thousand euros in the third quarter of 2015, as against 21,592 thousand euros in the third quarter of 2014. In the first nine months of 2015, sales and marketing expenses were equal to 72,219 thousand euros (65,647 thousand euros in 2014). This item consists mainly of marketing costs incurred to promote and distribute DiaSorin products, costs attributable to the direct and indirect sales force and the cost of the technical support offered together with the Group-owned equipment provided to customers under gratuitous loan contracts.

4. Research and development costs

The research and development costs incurred during the third quarter of 2015, which totalled 6,254 thousand euros (6,177 thousand euros in the same period of 2014), include all of the research and development outlays that were not capitalized for a total of 3,501 thousand euros (3,458 thousand euros in the third quarter of 2014), costs incurred to register the products offered for sale and meet quality requirements totalling 2,215 thousand euros (1,973 thousand euros in 2014), and the amortization of capitalized development costs equal to 538 thousand euros (746 thousand euros in the third quarter of 2014).

In the first nine months of 2015, the research and development costs amounted to 18,924 thousand euros (18,553 thousand euros in 2014) and include research costs equal to 10,829 thousand euros (10,719 thousand euros in 2014), costs incurred to register the products offered for sale and meet quality requirements totalling 6,492 thousand euros (6,048 thousand euros in 2014) and the amortization of development costs totalling 1,603 thousand euros (1,786 thousand euros in 2014).

In the third quarter of 2015, the Group capitalized development costs amounting to 444 thousand euros (688 thousand euros in the third quarter of 2014), for a total of 1,285 thousand euros in the first nine months of 2015 (1,047 thousand euros in 2014).

5. General and administrative expenses

General and administrative expenses, which include expenses incurred for corporate management activities, Group administration, finance and control, information technology, corporate organization and insurance, totalled 13,728 thousand euros in the third quarter of 2015 (12,377 thousand euros in 2014). In the first nine months of 2015, general and administrative expenses amounted to 40,720 thousand euros (36,669 thousand euros in 2014).

6. Other operating income (expense)

A breakdown of other operating income (expense) is provided below:

(in thousands of euros)	**3rd quarter 2015**	**3rd quarter 2014**	**01.01 – 09.30 2015**	**01.01 - 09.30 2014**
Trade-related foreign exchange gains and losses	(3,065)	451	(3,015)	1,140
Tax expenses	(538)	(473)	(1,465)	(1,261)
Additions to the allowances for doubtful accounts and additions to provisions for risks and charges	(1,189)	(70)	(2,736)	(956)
Out-of-period items and other operating income (expense)	(146)	(36)	(594)	367
Non-recurring expenses	-	-	-	(1,218)
Other operating income (expense)	**(4,938)**	**(128)**	**(7,810)**	**(1,928)**

This item reflects other income from operations that cannot be allocated to specific functional areas (such as gains and losses on asset sales, government grants, insurance settlements, reversals of unused provisions, additions to provisions for risks, incidental taxes and fees, out-of-period income and charges).
In the first nine months of 2015, non-recurring expenses relate to expenses occurred to support the reorganization and simplify the Norwegian branch structure and to support the reorganization of the French branch.

7. Financial expense/(income)

The table below provides a breakdown of financial income and expense:

(in thousands of euros)	**3rd quarter 2015**	**3rd quarter 2014**	**01.01 - 09.30 2015**	**01.01 – 09.30 2014**
Fees on factoring transactions	(301)	(333)	(760)	(970)
Interest and other financial expenses	(167)	(288)	(607)	(871)
Interest on pension funds	(141)	(248)	(421)	(562)
Share of the profit/(loss) of equity method investee	(109)	(107)	(425)	(266)
Interest and other financial income	244	724	1.424	1,351
Fair value measurement of financial instruments	10	(721)	269	(767)
Translation adjustment	(819)	1,054	(2,003)	1,630
Net financial income (expense)	**(1,283)**	**81**	**(2,523)**	**(455)**

In the third quarter of 2015, the Group collected interests accrued on past-due positions amounting to 83 thousand euros (596 thousand euros in the third quarter of 2014), totalling 900 thousand euros in the first nine months of 2015 (801 thousand euros in 2014) together with interests accrued on financial balances equal to 161 thousand euros (128 thousand euros in the same period of 2014) totalling 524 thousand euros in the first nine months of 2015 (550 thousand euros in the same period of 2014).

8. Income taxes

The income tax expense recognized in the income statement amounted to 12,102 thousand euros in the third quarter of 2015 (10,920 thousand euros in the same period of 2014). The tax burden was equal to 34.3%, up from 33.9% recorded in the third quarter of 2014, mainly as a result of the computation of the Group's taxable profit across the different geographic areas.

The income tax expense amounted to 37,118 thousand euros in the first nine months of 2015 (33,799 thousand euros in 2014). The tax rate decreased to 34% from 35.5% in the first nine months of 2014, as a result of non-deductible taxes withheld on dividends the Group's Parent Company received from foreign subsidiaries (11,217 thousand euros in 2015 as against 21,397 thousand euros in 2014) and, lastly, a lower tax rate in Italy following the introduction of regulatory amendments to help economic recovery.

9. Earnings per share

Basic earnings per share and diluted earnings per share totalled 0.42 euros in the third quarter of 2015 (0.40 in the third quarter of 2014) and 1.31 euros in the first nine months of 2015 (1.13 in the first nine months of 2014).

Basic earnings per shares were computed by dividing the net profit attributable to the shareholders by the weighted average number of shares outstanding during the year (equal to 54,859 thousand euros at September 30, 2015).
The dilutive effect of stock option plans granted by DiaSorin S.p.A, determined by excluding tranches assigned to a price higher than the average price of the ordinary shares in 2015, is not relevant.

<u>**Consolidated statement of financial position**</u>

10. Property, plant and equipment

The table below shows the changes that occurred in this account as of September 30, 2015:

(in thousands of euros)	**At December 31, 2014**	**Additions**	**Change in the scope of consolida-tion**	**Deprecia-tion**	**Divest-ments**	**Transla-tion differences**	**Reclassifi-cations and other changes**	**At September 30, 2015**
Land	2,345	-	-	-	-	22	-	2,367
Buildings	4,576	177	-	425	-	162	9	4,499
Plant and machinery	8,981	1,021	-	1,472	8	65	2,954	11,541
Manufacturing and distribution equipment	42,504	16,814	859	15,545	1,247	151	785	44,321
Other assets	7,190	942	-	1,140	25	106	(48)	7,025
Construction in progress and advances	6,611	1,441	-	-	75	55	(4,035)	3,997
Total property, plant and equipment	**72,207**	**20,395**	**859**	**18,582**	**1,355**	**561**	**(335)**	**73,750**

Additions to manufacturing and distribution equipment include purchases of medical equipment amounting to 14,599 thousand euros compared with 14,628 thousand euros at September 30, 2014. Depreciation for the period totalled 13,229 thousand euros, compared with 11,728 thousand euros in the same period of 2014.

11. Goodwill and other intangibles

A breakdown of intangible assets at September 30, 2015 is as follows:

(in thousands of euros)	**At December 31, 2014**	**Additions**	**Change in the scope of consolida-tion**	**Deprecia-tion**	**Transla-tion differences**	**Divest-ments and other changes**	**At September 30, 2015**
Goodwill	67,703	-	-	-	268	-	67,971
Development costs	13,825	1,285	-	1,603	270	-	13,777
Concessions, licenses and trademarks	26,175	866	2,818	2,650	(286)	300	27,223
Industrial patents and intellectual property rights	9,028	186	-	1,852	(53)	35	7,344
Advances and other intangibles	219	19	-	45	2	-	195
Total intangible assets	**116,950**	**2,356**	**2,818**	**6,150**	**201**	**335**	**116,510**

Goodwill amounted to 67,971 thousand euros at September 30, 2015 (67,703 thousand euros at December 31, 2014). The upward trend compared with December 31, 2014 also reflects the translation effect on the goodwill allocated to the DiaSorin U.S.A., DiaSorin Brazil and DiaSorin South Africa CGUs, for a positive amount equal to 268 thousand euros.

12. Equity investments

A breakdown of equity investments, which totalled 223 thousand euros at September 30, 2015 (506 thousand euros at December 31, 2014) is provided below:

(in thousands of euros)	At December 31, 2014	Additions	Share of the profit/(loss) of investees accounted for using the equity method	Translation differences	At September 30, 2015
Equity investment valued using the equity method:					
DiaSorin Trivitron Healthcare Private Limited	479	112	(425)	30	196
Equity investment valued at cost:					
DiaSorin Deutschland Unterstuetzungskasse GmbH	26	-	-	-	26
Consorzio Sobedia	1	-	-	-	1
Total equity investments	**506**	**112**	**(425)**	**30**	**223**

Equity investments are valued at cost and they are not consolidated because they are not operational. Their impact on the Group's total assets and liabilities, financial position and bottom-line result is not material. Moreover, the valuation of these investments by the equity method would not have an effect materially different from that produced by the cost approach.

13. Deferred-tax assets and deferred-tax liabilities

Deferred-tax assets amounted to 21,094 thousand euros (22,194 thousand euros at December 31, 2014). They relate to consolidated companies that have deferred-tax assets in excess of deferred-tax liabilities and to consolidation adjustments. Deferred-tax liabilities, which totalled 3,008 thousand euros (3,008 thousand euros at December 31, 2014) relate to consolidated companies that have deferred-tax liabilities in excess of deferred-tax assets. They are shown on the liabilities side of the statement of financial position.

The balance reflects the net deferred-tax assets computed on the consolidation adjustments (mainly from the elimination of unrealized gains on intra-Group transactions) and on temporary differences between the asset and liabilities amounts used to prepare the quarterly report and the corresponding amounts used by the consolidated companies for tax purposes.

Deferred-tax assets were recognized in the financial statements when their future use was deemed to be probable. The same approach was used to recognize the benefit provided by the use of tax loss carry forwards, most of which, under current laws, can be brought forward indefinitely.
Based on the multi-year plans prepared by the Group's management, the Group is expected to generate sufficient taxable income in future years to allow for the full recovery of the abovementioned amounts.

An analysis of deferred-tax assets, net of offsettable deferred-tax liabilities, is provided below:

(in thousands of euros)	**09/30/2015**	**12/31/2014**
Deferred-tax assets	21,094	22,194
Deferred-tax liabilities	(3,008)	(3,008)
Total net deferred-tax assets	**18,086**	**19,186**

14. Other non-current assets

Other non-current assets amounted to 1,094 thousand euros at September 30, 2015 (2,884 thousand euros at December 31, 2014). They consist mainly of trade receivable from the Brazilian subsidiary due beyond 12 months.

15. Inventories

A breakdown of inventories, which totalled 106,163 thousand euros (101,320 thousand euros at December 31, 2014) is provided below:

(in thousands of euros)	**09/30/2015**			**12/31/2014**		
	Gross amount	**Provisions for write-downs**	**Net amount**	**Gross amount**	**Provisions for write-downs**	**Net amount**
Raw materials and supplies	32,957	(2,102)	30,855	30,202	(1,804)	28,398
Semi-finished goods	40,604	(2,871)	37,733	40,834	(2,758)	38,076
Finished goods	39,228	(1,653)	37,575	36,426	(1,580)	34,846
Total	**112,789**	**(6,626)**	**106,163**	**107,462**	**(6,142)**	**101,320**

The increase of 4,843 thousand euros in ending inventories compared with December 31, 2014 (out of which 1 million euros related to the exchange rate effect) is due to the increase in manufacturing volumes to support growing revenues.

The table below shows the changes that occurred in the provisions for inventory write-downs:

(in thousands of euros)	**09/30/2015**	**12/31/2014**
Opening balance	**6,142**	**5,971**
Additions for the period	1,106	2,105
Utilizations/Reversals for the period	(673)	(2,242)
Translation differences and other changes	51	308
Ending balance	**6,626**	**6,142**

16. Trade receivables

Trade receivables totalled 105,545 thousand euros at September 30, 2015 (109,521 thousand euros at December 31, 2014). The table that follows shows the changes that occurred in the allowance for doubtful accounts, which amounted to 9,994 thousand euros (8,882 thousand euros at December 31, 2014):

(in thousands of euros)	**09/30/2015**	**12/31/2014**
Opening balance	**8,882**	**8,100**
Additions for the period	2,240	1,507
Utilizations/Reversals for the period	(255)	(791)
Translation differences and other changes	(873)	66
Ending balance	**9,994**	**8,882**

In order to bridge the gap between contractual payment terms and actual collection times, the Group uses factoring transactions to assign its receivables without recourse. In the first nine months of 2015, the receivables assigned by the Group's Parent Company amounted to 28,730 thousand euros (33,840 thousand euros in the same period of the previous year).

17. Other current assets

Other current assets amounted to 10,375 thousand euros (10,291 thousand euros at December 31, 2014). They consist of 2,960 thousand euros in accrued income and prepaid expenses for insurance, interest, rentals and government grants (1,999 thousand euros at December 31, 2014) and 4,490 thousand euros in tax credits for tax prepayments and for foreign taxes withheld (5,415 thousand euros at December 31, 2014).

18. Cash and current financial assets

Cash and cash equivalents amounted to 176,509 thousand euros at September 30, 2015 (144,855 thousand euros at December 31, 2014). They consist of balances in banks accounts and short-term bank deposits. More detailed information is provided in the Statement of Cash Flows above.

Current financial assets amounted to 57,581 thousand euros at September 30, 2015 (24,963 thousand euros at December 31, 2014) and include short-term cash investments that do not qualify as cash equivalents, as defined in Paragraph 7 of IAS 7, because the overall term of the securities involved was longer than three months at the date of purchase.
In particular, other current financial assets include term deposits exceeding three months opened by the Group Parent Company in the first nine months of 2015 (30 million euros) and the U.S. subsidiary (30 million dollars). No penalties will be applied in case of prematurely closure and interests will not be paid.
At September 30, 2015 the item includes the fair value of the Group's Parent company' forward contract for sales of foreign currency which was positive by 269 thousand euros, as provided below:

(in thousands of euros)	**09/30/2015**	**12/31/2014**
Short and long term-bank deposits	57,312	24,963
Forward contracts	269	-
Other current financial assets	**57,581**	**24,963**

19. Shareholders' equity

Share capital

At September 30, 2015, the fully paid-in share capital consisted of 55,948,257 million common shares, par value of 1 euro each. No changes occurred compared with December 31, 2014.

Treasury shares

Treasury shares amounted to 26,631 thousand euros at September 30, 2015 (44,045 thousand euros at December 31, 2014).
The decrease of 17,414 thousand euros compared with December 31, 2014 is due to the exercise of some tranches of the 2010 stock option Plan by the Group's Parent company employees and its subsidiaries.

Additional paid-in capital

This reserve amounted to 18,155 thousand euros at September 30, 2015 and no changes occurred compared with December 31, 2014.

Statutory reserve

This reserve amounted to 11,190 thousand euros at September 30, 2015 and no changes occurred compared with December 31, 2014.

Other reserves and retained earnings

A breakdown of other reserves and retained earnings is as follows:

(in thousands of euros)	**09/30/2015**	**12/31/2014**	**Change**
Currency translation reserve	23,766	12,322	11,444
Reserve for treasury shares	26,631	44,045	(17,414)
Stock option reserve	1,648	4,781	(3,133)
Gains/(losses) on remeasurement of defined benefit plans	(7,228)	(7,537)	309
Retained earnings	379,283	307,271	72,012
IFRS transition reserve	(2,973)	(2,973)	-
Other reserves	342	342	-
Total Other reserves and retained earnings	**421,469**	**358,251**	**63,218**
of which minority interest	***214***	***204***	***10***

Currency translation reserve
The currency translation reserve totalling 23,766 thousand euros (12,322 thousand euros at December 31, 2014) includes the exchange differences arising from the translation of equity of consolidated subsidiaries, whose financial statements are denominated in foreign currencies, at the exchange rate in effect at the end of the year. This reserve increased by 11,444 thousand euros, due mainly to changes in the exchange rates of the US dollar vis-à-vis the euro.

Reserve for treasury shares
At September 30, 2015, the reserve for treasury shares amounted to 26,631 thousand euros (44,045 thousand euros at December 31, 2014). This reserve was established pursuant to law (Article 2357 ter of the Italian Civil Code) due to purchases of treasury shares made during 2011. The change of 17,414 thousand euros compared with December 31, 2014 is due to the exercise of some tranches of the 2010 stock option Plan.

Stock option reserve
The balance in the stock option reserve, which amounted to 1,648 thousand euros (4,781 thousand euros at December 31, 2014) refers to the stock option plans active at September 30, 2015. The changes in the reserve that occurred at September 30, 2015 included both an increase due to the recognition of the overall cost of the stock option Plans (933 thousand euros) that was posted and recognized in the income statement as a labour costs included in general and administrative expenses, and a decrease of 4,066 thousand euros as a result of the options exercised throughout 2015.

Gains/(losses) on remeasurement of defined benefit plans
At September 30, 2015 this item, negative by 7,228 thousand euros (7,537 thousand euros at December 31, 2014) includes net gains of the period related to the actuarial assessment of the Group's defined-benefit plans amounting to 309 thousand euros, net of tax effect (59 thousand euros).

Retained earning
Retained earnings amounted to 379,283 thousand euros (307,271 thousand euros at December 31, 2014). The change in retained earnings, equal to 72,012 thousand euros compared with December 31, 2014, is due to:

- the appropriation of the consolidated net profit earned by the Group in 2014 (84,074 thousand euros);
- the dividend distribution to the shareholders, amounting to 32,936 thousand euros, and approved in the Shareholders' Meeting held on April 22, 2015 (equal to 0.60 euros per share);
- the exercise of some tranches of the 2010 Stock Option Plan, which resulted in a positive change of 20,874 thousand euros and in the sale of treasure shares.

IFRS transition reserve
The IFRS transition reserve was established on January 1, 2005, upon first-time adoption of the IFRSs as an offset to the adjustments recognized to make the financial statements prepared in accordance with Italian accounting principles consistent with IFRS requirements, net of the applicable tax effect (as required by and in accordance with IFRS 1). This reserve has not changed since it was first established.

Other reserves
This item includes the consolidation reserve equal to 904 thousand euros, net of the discounted repurchase price of the Chinese subsidiary's minority interest together with the put option right granted to the minority shareholder amounting to 562 thousand euros. No changes occurred compared with December 31, 2014.

20. Borrowings and other financial liabilities

Borrowings and other financial liabilities totalled 2,222 thousand euros at September 30, 2015 (3,217 thousand euros at December 31, 2014). A breakdown is as follows (value in thousands):

Lender	**Currency**	**Current portion**	**Non-current portion**	**Total**
Santander	BRL	9,000	-	9,000
	Amount in €	2,009	-	2,009
IMI MIUR	€	213	-	213
Total owed to financial institutions		**2,222**	**-**	**2,222**

The table below lists the changes that occurred in the facilities outstanding as of September 30, 2015 compared with December 31, 2014 (amounts in thousands of euros):

Lender	At December 31, 2014	Repayments	Currency translation differences	Amortized cost effect	At September 30, 2015
Santander	2,795	-	(786)	-	2,009
IMI MIUR	418	(213)	-	8	213
Finance leases	4	(3)	(1)	-	-
Total owed to financial institutions	**3,217**	**(216)**	**(787)**	**8**	**2,222**

The following amount of 213 thousand euros was repaid to IMI-MIUR in the first nine months of 2015.
There were no changes in contract terms compared with December 31, 2014 and DiaSorin was in compliance with all of the operating and financial covenants of the existing loan agreements.

21. Provisions for employee severance indemnities and other employee benefits

The balance in this account reflects all of the Group pension plan obligations, other post-employment benefits and benefits payable to employees when certain requirements are met. Group companies provide post-employment benefits to their employees by contributing to external funds and by funding defined- contribution and/or defined-benefit plans.
The manner in which these benefits are provided varies depending on the applicable statutory, tax-related and economic conditions in the countries where Group companies operate. As a rule, benefits are based on each employee’s level of compensation and years of service.

Defined-contribution plans

Certain Group companies pay contributions to private funds or insurance companies pursuant to a statutory or contractual obligation or on a voluntary basis. With the payment of these contributions, the companies in question absolve all of their obligations. The liability for contributions payable is included under other current liabilities. The cost attributable to each year, which accrues based on the services provided by employees, is recognized as a labour cost of the relevant organizational unit.

Defined-benefit plans

The Group’s pension plans that qualify as defined-benefit plans include the provisions for employee severance indemnities in Italy, the Alecta system in Sweden and the U-Kasse pension plan and Direct Covenant system in Germany.
The liability owed under these plans is recognized at its actuarial value using the projected unit credit method; actuarial gains and losses resulting from the determination of these liabilities are credited or charged to equity in the statement of comprehensive income in the period in which they arise.

Other employee benefits

The Group also provides its employees with additional long-term benefits, which are paid when employees reach a predetermined length of service. In these cases, the value of the liability recognized in the financial statements reflects the probability that these benefits will be paid and the length of time for which they will be paid. The liability owed under this plan is recognized at its actuarial value using the projected unit credit method. Any resulting actuarial gains or losses are recognized in the income statement.

The table that follows lists the Group's main employee benefit plans that are currently in effect:

(in thousands of euros)	**09/30/2015**	**12/31/2014**	**Change**
Employee benefits			
provided in:			
- Italy	5,411	6,144	(733)
- Germany	22,973	22,471	502
- Sweden	2,970	3,003	(33)
- Other countries	530	488	42
Total employee benefits	**31,884**	**32,106**	**(222)**
broken down as follows:			
- Defined-benefit plans			
Provision for employee severance indemnities	*4,218*	*4,793*	*(575)*
Other defined-benefit plans	*25,943*	*25,474*	*469*
	30,161	30,267	(106)
- Other long-term benefits	1,723	1,839	(116)
Total employee benefits	**31,884**	**32,106**	**(222)**

The table below shows the main changes that occurred in the Group's employee benefit plans in the first nine months of 2015 (amounts in thousands of euros):

(in thousands of euros)	**Defined-benefit plans**	**Other benefits**	**Total employee benefits**
Balance at 12/31/2014	**30,267**	**1,839**	**32,106**
Interest payable	420	1	421
Actuarial losses/(gains) recognized in income statement	-	(114)	(114)
Actuarial losses/(gains) recognized directly in equity	(368)	-	(368)
Current service cost	590	121	711
Benefits paid	(743)	(125)	(868)
Translation differences and other changes	(5)	1	(4)
Balance at 09/30/2015	**30,161**	**1,723**	**31,884**

22. Other non-current liabilities

Other non-current liabilities, which totalled 3,346 thousand euros at September 30, 2015 (4,677 thousand euros at December 31, 2014) include provisions for risks and charges established in connection with pending or contingent legal disputes and for supplemental severance benefits owed to sales agents.

The table that follows shows the changes that occurred in these provisions:

(in thousands of euros)	**09/30/2015**	**12/31/2014**
Opening balance	**3,679**	**3,858**
Additions for the period	171	876
Utilizations/Reversals for the period	(1,154)	(1,065)
Translation differences and other changes	(324)	10
Ending balance	**2,372**	**3,679**

23. Trade payables

Trade payables, which totalled 35,106 thousand euros at September 30, 2015 (39,311 thousand euros at December 31, 2014) represent amounts owed to external suppliers for the purchase of goods and services. There are no amounts due after one year.

24. Other current liabilities

Other current liabilities of 30,582 thousand euros at September 30, 2015 (30,573 thousand euros at December 31, 2014) consist mainly of amounts owed to employees for additional monthly payments to be paid for a total of 21,225 thousand euros (20,734 thousand euros at December 31, 2014), contributions payable to social security and health benefit institutions equal to 2,176 thousand euros (2,867 thousand euros at December 31, 2014) and accruals and deferred charges amounting to 1,366 thousand euros (2,550 thousand euros at December 31, 2014).

25. Income taxes payable

The balance of 10,199 thousand euros at September 30, 2015 (8,967 thousand euros at December 31, 2014) represents the income tax liability for the profit earned in the period, net of estimated payments made and amounts owed for other indirect taxes and fees.

26. Commitments and contingent liabilities

Significant commitments and contractual obligations

Significant contractual obligations include the agreements executed by DiaSorin S.p.A., the Group's Parent Company, and Stratec in connection with the development and production of the new chemiluminescent diagnostic system (LIAISON XL). The supply contract signed by DiaSorin and Stratec calls for the latter to manufacture and supply exclusively to DiaSorin the LIAISON XL analyser. The Group has agreed to purchase a minimum number of systems. However, the projected commitment is deemed to be significantly lower than the normal level of capital investment that would be required for current or future equipment production. As a result, net invested capital is not expected to undergo significant structural changes in the future as a result of this commitment.

Contingent liabilities

The DiaSorin Group operates globally. As a result, it is exposed to the risks that arise from the complex laws and regulations that apply to its commercial and manufacturing activities.
The Group believes that, overall, the amounts set aside for pending legal disputes in the corresponding provision for risks are adequate.

27. Entries resulting from atypical and/or unusual transactions

As required by Consob Communication No. DEM/6064296 of July 28, 2006, the Company declares that, in the first nine months of 2015, the Group did not execute atypical and/or unusual transactions, as defined in the abovementioned Communication, according to which atypical and/or unusual transactions are transactions that, because of their significance/material amount, type of counterpart, subject of the transaction, method of determining the transfer price and timing of the event (proximity to the end of a reporting period), could create doubts with regard to: the fairness/completeness of the financial statement disclosures, the existence of a conflict of interest, the safety of the corporate assets and the protection of minority shareholders.

ANNEX I: THE COMPANIES OF THE DIASORIN GROUP AT SEPTEMBER 30, 2015

	Head office location	Currency	Share capital (*)	Par value per share or partnership interest	% interest held directly	Number of shares or partnership interests held
Equity investments consolidated line by line						
DiaSorin S.A/N.V.	Bruxelles (Belgium)	**EUR**	1,674,000	6,696	99.99%	249
DiaSorin Ltda	San Paolo (Brazil)	**BRL**	30,380,977	1	99.99%	30,380,976
DiaSorin S.A.	Antony (France)	**EUR**	960,000	15,3	99.99%	62,492
DiaSorin Iberia S.A.	Madrid (Spain)	**EUR**	1,453,687	6,01	99.99%	241,877
DiaSorin Ltd	Oldbury (United Kingdom)	**GBP**	500	1	100.00%	500
DiaSorin Inc.	Stillwater (USA)	**USD**	1	0,01	100.00%	100
DiaSorin Canada Inc	Mississauga (Canada)	**CAD**	200,000	N/A	-	100 Class A common shares
DiaSorin Mexico S.A de C.V.	Mexico City (Mexico)	**MXP**	63,768,473	1	99.99%	49,999
DiaSorin Deutschland GmbH	Dietzenbach (Germany)	**EUR**	275,000	275,000	100.00%	1
DiaSorin AB	Solna (Sweden)	**SEK**	5,000,000	100	100.00%	50,000
DiaSorin Ltd	Rosh Haayin (Israel)	**ILS**	100	1	100.00%	100
DiaSorin Austria GmbH	Wien (Austria)	**EUR**	35,000	35,000	100.00%	1
DiaSorin Czech s.r.o.	Prague (Czech Republic)	**CZK**	200,000	200,000	100.00%	1
DiaSorin Diagnostics Ireland Limited	Dublin (Ireland)	**EUR**	3,923	0,01	100.00%	392,282
DiaSorin Ireland Limited	Dublin (Ireland)	**EUR**	163,202	1,20	-	136,002
DiaSorin I.N.UK Limited	Dublin (Ireland)	**EUR**	7,826,072	0,01	-	782,607,110
DiaSorin South Africa (PTY) Ltd	Johannesburg (South Africa)	**ZAR**	101	1	100.00%	101
DiaSorin Australia (Pty) Ltd	Sydney (Australia)	**AUD**	3,300,000	33,000	100.00%	100
DiaSorin Ltd	Shanghai (China)	**RMB**	1,211,417	1	80.00%	96,000
DiaSorin Switzerland AG	Risch (Switzerland)	**CHF**	100,000	100	100.00%	1,000
DiaSorin Poland sp. z o.o.	Warsaw (Poland)	**PLN**	500,000	50	100.00%	100

(*) Amounts stated in the local currency

Company	Head office location	Currency	Share capital (*)	Par value per share or partnership interest	% interest held directly	Number of shares or partnership interests held
Equity investment valued using the equity method						
DiaSorin Trivitron Healthcare Private Limited	Chennai (India)	**INR**	212,295,610	10	-	10,827,076
Equity investment valued at cost						
DiaSorin Deutschland Unterstuetzungskasse GmbH	Dietzenbach (Germany)	**EUR**	25,565	1	-	1
Consorzio Sobedia	Saluggia (Italy)	**EUR**	5,000	N/A	20.00%	1

(*) Amounts stated in the local currency

DECLARATION IN ACCORDANCE WITH THE SECOND SUBSECTION OF ART. 154-BIS, PART IV, TITLE III, SECOND PARAGRAPH, SECTION V-BIS, OF LEGISLATIVE DECREE NO. 58 OF FEBRUARY 24, 1998. "UNIFORM LAW ON FINANCIAL INTERMEDIATION ENACTED PURSUANT TO ARTICLES 8 AND 21 OF LAW NO. 52 OF FEBRUARY 6, 1996"

I, the undersigned, Luigi De Angelis, Officer Responsible for the preparation of corporate financial reports of DIASORIN S.p.A.

ATTEST

as required by the second subsection of Art. 154-*bis*, Part IV, Title III, Second Paragraph, Section V- bis, of Legislative Decree No. 58 of February 24, 1998, that, to the best of my knowledge, the financial information included in the present document corresponds to book of accounts and bookkeeping entries of the Company.

Saluggia, November 11, 2015

Luigi De Angelis

Officer Responsible for the preparation
of corporate financial reports
DIASORIN S.p.A.